



Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring

Raquel Álvarez^{a,c,d}, Laura Aramburu^{a,c,d}, Consuelo Gajate^b, Alba Vicente-Blázquez^{a,b,c,d}, Faustino Mollinedo^b, Manuel Medarde^{a,c,d}, Rafael Peláez^{a,c,d,*}

^a Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain

^b Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), E-28040 Madrid, Spain

^c Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain

^d Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain

ARTICLE INFO

Keywords:

Pyridine derivatives
Combretastatins, isocombretastatins and phenstatins
Solubility
Antimitotic
Docking

ABSTRACT

Colchicine site antimitotic agents typically suffer from low aqueous solubilities and are formulated as phosphate prodrugs of phenolic groups. These hydroxyl groups are the aim of metabolic transformations leading to resistance. There is an urgent need for more intrinsically soluble analogues lacking these hydroxyl groups. The 3,4,5-trimethoxyphenyl ring of combretastatin A-4 is a liability in terms of solubility but it is considered essential for high cytotoxic and tubulin polymerization inhibitory (TPI) activity. We have synthesized 36 new analogues of combretastatin A-4 replacing the trimethoxyphenyl moiety with more polar pyridine based moieties, measured their aqueous solubility, and studied their anti-proliferative effects against 3 human cancer cell lines. We show here that pyridine rings can be successful replacements for the trimethoxyphenyl ring, resulting in potent and more soluble analogues. The more straightforward replacement, a 2,6-dimethoxypyridine ring led to inactive analogues, but a 2-methoxy-6-methylsulfanylpuridine moiety led to active analogues when combined with different B rings. This replacement led to potent cytotoxic activity against sensitive human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies. Cell cycle analysis also showed apoptotic responses following treatment. Docking studies suggested binding at the colchicine site of tubulin and provided a good agreement with the observed SAR. A 2-methoxy-6-methylsulfanylpuridine moiety is a good trimethoxyphenyl ring replacement for the development of new colchicine site ligands.

1. Introduction

The microtubules are part of the cytoskeleton of the eukaryotic cells and are involved in the maintenance of the cell shape, in the intracellular trafficking of organelles and vesicles, in the functioning of cilia and flagella and in the cellular events occurring during the mitotic cell division [1]. These essential functions are dependent on the dynamic polymerization equilibria of microtubules consisting on assembly and disassembly from the microtubules of their main constituents, the

$\alpha\beta$ -tubulin heterodimers. Many anti-tumor and anti-parasitic drugs exert their actions by altering the dynamic behaviour of the microtubules (microtubule-targeting agents or MTAs), some promoting (microtubule stabilizing agents or MSAs) and some opposing (microtubule destabilizing agents or MDAs) polymerization depending on their preferential binding to tubulin or the microtubules [2]. MTAs usually bind specifically to one of the several known binding sites available in the tubulin heterodimers, such as the taxanes, the vinca alkaloids, or the colchicine sites, thus determining their effects. The binding of MDAs to

* Corresponding author at: Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Facultad de Farmacia, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.

E-mail addresses: raquelalvarez@usal.es (R. Álvarez), lauramvil@usal.es (L. Aramburu), cgajate@cib.csic.es (C. Gajate), avicentblazquez@usal.es (A. Vicente-Blázquez), fmollin@cib.csic.es (F. Mollinedo), medarde@usal.es (M. Medarde), pelaez@usal.es (R. Peláez).

<https://doi.org/10.1016/j.bioorg.2020.103755>

Received 31 December 2019; Received in revised form 28 February 2020; Accepted 11 March 2020

Available online 13 March 2020

0045-2068/ © 2020 Elsevier Inc. All rights reserved.




Fig. 1. Representative colchicine - site type ligands.

tubulin results in inhibition of the mitotic spindle (anti-mitotic effect), cell cycle arrest at the metaphase to anaphase transition with cells accumulating in the G₂/M phase, and late apoptosis of cancer cells [3] and a rapid *in vivo* collapse of the vasculature (vascular disrupting agents or VDAs) which shuts down solid-tumours blood flow, thus causing tumor death [4,5].

The colchicine site is located at the interface between the tubulin monomers and drug binding prevents the curved to straight transition of tubulin heterodimers, thus blocking tubulin polymerization (MDA). In recent years many colchicine site ligands (Fig. 1), both natural and synthetic, have been discovered and applied as VDAs, such as the phosphate prodrugs of combretastatin A-4 (CA4P, fosbretabulin) and combretastatin A-1 (CA1P, Oxi4503) and the amino analogue AVE8062, currently in clinical development [4–6] mainly in combination therapy together with cytotoxic drugs. Treatment with VDAs causes a rapid initial central tumour necrosis soon followed by regrowth of a peripheral rim of resistant viable cancer cells to the necrotic area causing recurrence and metastasis [7,8]. Cancer cells treated with combretastatin A-4 show innate and acquired resistance mechanisms, including adaptation to the hypoxic conditions and reestablishment of the vasculature in response to the reduction in blood supply as well as direct resistance to the drug. The main limitations of combretastatins are a low intrinsic aqueous solubility, the inactivation by isomerization of the *Z* active isomer to the thermodynamically more stable *E* isomer and the phase I and II metabolic transformations [9,10]. The low solubility has been mostly overcome by means of prodrugs incorporating solubilizing groups such as phosphates on the hydroxyl group of combretastatin A-4 [11] but this group is also involved in phase II metabolic transformations leading to resistance [12]. The isomerization problem has been tackled by formation of different cycles on the olefin which block the configuration [13,14] or by means of configurationally invariable one-atom bridges, such as those of benzophenones (e.g. phenstatin) [11], 1,1-diarylethenes (e.g. isocombretastatin A-4) [15], and diarylamines (e.g. verubulin) [16].

The 3,4,5-trimethoxyphenyl ring of combretastatin A-4 (A ring) has long been considered as essential for high tubulin inhibitory and cytotoxic potency and is present in many derivatives despite its highly unfavourable pharmacokinetic properties due to its high volume and hydrophobicity [9]. It also suffers phase I metabolic reactions associated with inactivation by olefin isomerization, mainly after *O*-demethylation of the central methoxy group [10]. Recently, replacement of the lateral methoxy groups by halogen atoms (mainly iodine or bromine) has been shown to increase cytotoxic potency, but with no pharmacokinetic advantage [17]. Attempts to improve the pharmacokinetics of colchicine site ligands by increasing the polarity of the A ring, as for instance with pyridine rings as in ABT-751 leads to substantial potency reductions [18], and only recently a new family of pyridine-chalcones with high potency has been described [19].

Here we have explored the possibility of replacing the 3,4,5-trimethoxyphenyl ring (A ring) of combretastatin and isocombretastatin analogues with a pyridine moiety, with the added heterocyclic nitrogen replacing the attachment carbon of the central methoxy group. We anticipated that this substitution might preserve the polar interaction with the thiol group of Cys241β of tubulin that is usually considered as a key interaction in colchicine analogues, while significantly improving the polarity and aqueous solubility of the resulting analogues. We have also successfully introduced methylsulfanyl groups in replacement of

one of the lateral methoxy groups to partially compensate for the size reduction associated with the loss of the central methoxy group. In an attempt to explore the different SARs observed for colchicine site analogues with different bridge lengths we have combined the pyridine rings with 1,2-ethynylene (combretastatin), 1,1-ethynylidene (isocombretastatin), and carbonyl (phenstatin) bridges and with different B rings that have produced potent analogues when combined with the classical 3,4,5-trimethoxyphenyl ring, such as naphthalene [20,21], indoles with and without 3-substituents [21–23], 4-methoxy- [15], and 4-dimethylaminophenyl rings [24]. As expected, substantial overall solubility improvements were achieved, and highly potent tubulin polymerization inhibition was observed for several analogues, with even submicromolar IC₅₀ values, better than those observed for combretastatin A-4. Cytotoxic potencies in the mid nanomolar range were also found for the most potent derivatives against sensitive HeLa human cervix epithelioid carcinoma and HL-60 human acute myeloid leukemia cell lines and submicromolar against the combretastatin A-4-resistant colon adenocarcinoma (HT-29) cell line. These effects were accompanied by accumulation of cells in the G₂/M cell cycle phase after 24 h of drug treatments at concentrations of 100 nM and significant sub-G₀/G₁ cell fractions after 48 h treatment. The effects of the compounds on the cytoskeleton were confirmed by immunofluorescence studies. These results show that replacement of the A phenyl ring of combretastatin analogues by pyridine rings is a suitable strategy for achieving improved water solubility while maintaining high cytotoxic potency through tubulin polymerization inhibition.


2. Results and discussion

2.1. Chemistry

2.1.1. Chemical synthesis

We have employed the Wittig reaction between appropriate phosphonium ylides and aromatic aldehydes for the synthesis of the combretastatins, and nucleophilic additions of aryl-lithium derivatives to pyridine carboxylic acids, prepared from citrazinic acid as shown in Scheme 1, for the synthesis of diarylketones, as shown in Schemes 2–3 [15,21]. We synthesized 2,6-dichloroisonicotinic acid (1) from citrazinic acid by treatment with neat phosphorous oxychloride and tetramethylammonium chloride [25]. Nucleophilic aromatic substitutions of the chlorine atoms with sodium methoxide or sodium methanethiolate at room temperature gave the monosubstituted acids 2 and 3. Substitution of the second chlorine atom required heating, and 2,6-dimethoxyisonicotinic acid (4) was prepared from either citrazinic acid or 2 with excess sodium methoxide in refluxing diglyme. 2-Methoxy-6-(methylsulfanyl)isonicotinic acid (5) could not be prepared by heating acid 2 in the presence of sodium methanethiolate, but was obtained in good yield from 3 by treatment with excess sodium methoxide in refluxing diglyme. Acids 4 and 5 were used in the synthesis of the pyridophenones. For the Wittig reactions, the carboxylic acids were reduced with LAH. The benzylic alcohol 6 was oxidized to the aldehyde 8 and benzylic alcohol 7 was converted into the corresponding benzylic bromide 9 by treatment with hydrobromic acid in acetic acid. Bromide 9 was rapidly transformed into the phosphonium salt 10 by treatment with triphenylphosphine in toluene.

We synthesized the combretastatins A (1,2-diarylethenes) by means of Wittig reactions between the phosphonium ylides formed by



Scheme 1. Reagents and conditions: (a) POCl₃, Me₄NCl, 140 °C, 24 h; (b) NaOMe, MeOH, room temperature, 24 h (**2**) or NaSMe, DMF, reflux, 24–48 h (**3**); (c) NaOMe, MeOH, diglyme, reflux, 24 h; (d) LiAlH₄, dry THF, 0 °C, 1 h; then room temperature, 24 h; (e) MnO₂; (f) HBr in AcOH, 0 °C, 24 h; (g) PPh₃, toluene, room temperature, 24–48 h; (h) **5**, EDCI, 4-DMAP, CH₂Cl₂, room temperature, 1 h, then NH₂NH₂, 24 h; (i) KOH, cat. tetrabutylammonium hydrogensulfate, MeI, CH₂Cl₂, room temperature, 24 h.


treatment of the phosphonium salts with *n*BuLi and *N*-methylindole-5-carbaldehyde (**11**), 3,4,5-trimethoxybenzaldehyde, 4-dimethylaminobenzaldehyde or *p*-anisaldehyde (**Scheme 2**). The *E* and *Z* isomers were chromatographically separated. Hydrogenation of the double bonds with Pd(C) yielded the combretastatins B. 2,3-Dihydrooxadiazoles were obtained by treatment of hydrazide **12** with *N*-methylindole-5-carbaldehyde, 4-dimethylaminobenzaldehyde or *p*-anisaldehyde in acetic anhydride.


The phenstatin and isocombretastatin analogues **24–44** were prepared as indicated in **Scheme 3**. We synthesized diaryl ketones **24–29** by means of nucleophilic additions of aryl-lithium reagents (prepared from the aryl bromides by treatment with *n*BuLi) to isonicotinic acids **2** and **3**. The ketones were transformed in the oximes **34–36** by treatment with hydroxylamine and in the 1,1-diarylethenes (isocombretastatins) **30–33** by Wittig reaction using methyltriphenylphosphonium iodide. Hydrogenation of isocombretastatin **31** yielded ethane derivative **37**. Nitration of **27** followed by reduction gave amine **39**. Formyl indoles **40** and **43** were prepared by Vilsmeier–Haack formylation. **40** was converted into cyanoindoles **41** and **42** via the oximes by an acetylation–elimination sequence. Acid derivative **44** was prepared from **43** by electrophilic substitution with phosgene followed by hydrolysis. Oxidation of the methylsulfanyl groups of **26** and **28** with *m*CPBA allowed us to obtain the corresponding sulfoxides (**45** and **47**) and sulfones (**46** and **48**).

The synthesized compounds sample different combinations of B rings and bridges that have previously been shown to provide potent colchicine site ligands, and thus allow for a significant exploration of the potential of the pyridine analogues as cytotoxic and tubulin polymerization inhibitory agents, and were subsequently used in the biological assays.

2.1.2. Aqueous solubility

The low aqueous solubility is one of the main problems encountered in the development to the clinic of colchicine site ligands. The replacement of phenyl rings by pyridines should result in a significantly improved water solubility due to the increased polarity. Additional structural modifications, such as the introduction of amino groups as in **39**, the introduction of polar groups at the indole 3 position or the oxidation of thioethers to sulfoxides or sulfones are also expected to improve it. We have measured the solubility of representative compounds in phosphate buffer at pH 7.0 using a shake-flask method, microfiltration and quantification of the dissolved compound by UV absorbance. Most of the compounds show a significant (more than ten-fold, see **table 1**) improvement with respect to combretastatin A-4 and ABT-751, representative drugs of a trimethoxyphenyl or a pyridine A ring in clinical trials, respectively. Most of the attempts to improve the solubility of colchicine site ligands have been directed at the B ring and involve prodrugs of the hydroxyl group at position 3, which in turn





Scheme 3. Synthesis of pyridylphenstatins, pyridyloximes and pyridylisocombretastatin analogues. Reagents and conditions: (a) i) ArBr, *n*BuLi, dry THF, -40°C , 1 h, then 2 or 3; ii) room temperature, 24 h; (b) i) CH₃-PPh₃I, *n*BuLi, dry THF, -40°C , 1 h; ii) **27** – **29**, room temperature, 24 h; (c) NH₂OH·HCl, MeOH, pyridine, reflux, 24 h; (d) H₂, Pd(C), room temperature, 24–48 h; (e) HNO₃, H₂SO₄, CH₂Cl₂, 0°C , 5 min; (f) Fe, EtOH/AcOH/H₂O (2:2:1), 100°C , 1 h; (g) i) POCl₃, dry DMF, 0°C , 30 min; ii) **28**, heat to room temperature or **32** and heat to 60°C , 2 h; (h) i) NH₂OH·HCl, MeOH, pyridine, reflux, 24 h; ii) Ac₂O, pyridine, 130°C , 24–48 h; (i) Phosgene, CH₂Cl₂, room temperature, 24–48 h; j) oxidation; k) *m*CPBA, CH₂Cl₂, room temperature, 24–48 h. Abbreviations: 3,4,5-TM = 3,4,5-trimethoxyphenyl; 4-MeOPh = 4-methoxyphenyl; 2-Naphth = 2-Naphthyl; 1-MeIND = *N*-methyl-5-indolyl; 4-NMe₂Ph = 4-dimethylaminophenyl.

Table 1
Aqueous solubility of representative compounds in phosphate buffer at pH 7.0.

Comp	Bridge	Ar _A	Ar _B	Solubility (μg/mL)
		X	Ar R	
CA-4	Combretastatin	–	–	1.04[26]
17	Combretastatin	SMe	1-MeIND	19.1
22	Oxadiazole	SMe	4-MeO-Ph	9.8
23	Oxadiazole	SMe	1-MeIND	12.8
27	Phenstatin	SMe	4-MeO-Ph	17.0
31	Isocombretastatin	SMe	4-MeO-Ph	10.9
33	Isocombretastatin	SMe	4-(NMe ₂)Ph	43.8
35	Oxime	SMe	1-MeIND	< 1
36	Oxime	SMe	4-(NMe ₂)Ph	4.6
39	Phenstatin	SMe	4-MeO-Ph	37.3
40	Phenstatin	SMe	1-MeIND	15.5
41	Phenstatin	SMe	1-MeIND	14.9
44	Isocombretastatin	SMe	1-MeIND	151.9
45	Phenstatin	SOMe	2-Naphth	34.5

constitutes a means for drug resistance. The substitution of a trimethoxyphenyl ring by a 2-methylsulfanyl-6-methoxypyridine results in a ten-fold solubility increase in the combretastatins (compare **17** with indolecombretastatin, with a solubility of 2.6 μg/mL) [22], but a more modest increase is observed for the isocombretastatins (compare **33** with its trimethoxyphenyl analogue, with a solubility of 30 μg/mL) [23]. The phenstatins show similar solubilities of circa 15 μg/mL, irrespective of the ring B (e.g. **27**, **40** or **41**) unless an additional solubilizing group such as an amino (**39**) or sulfoxide (**45**) group is present. Surprisingly, the oximes (e.g. **35** and **36**) are much less soluble than the corresponding isocombretastatins (e.g. **31** and **33**), whose solubilities are more dependent on the nature of the second aromatic ring.

2.2. Biology

2.2.1. Cell viability

We have assayed the effect of the synthesized compounds on cell viability by the XTT method against three types of human cancer cell lines (Table 2): HeLa human cervix epithelioid carcinoma, HL-60 human acute myeloid leukemia, and HT-29 human colon adenocarcinoma [27]. Combretastatins, phenstatins, oximes, and isocombretastatins carrying a 2,6-dimethoxypyridine ring, the most direct replacement of the 3,4,5-trimethoxyphenyl ring, are inactive, while analogues carrying a 2-methylsulfanyl-6-methoxypyridine are cytotoxic at submicromolar concentrations. These results indicate that the substitution of the trimethoxyphenyl ring by a pyridine moiety can be successful. The most potent compounds of the series inhibited cell proliferation in the indicated human cancer cell lines at very low drug concentrations, with IC₅₀ values in the double-digit nanomolar range. These IC₅₀ values are 5–25 times higher than those shown by combretastatin A-4 (IC₅₀ at a range between 10^{-9} and 10^{-8} M), one of the most potent compounds representative of the trimethoxyphenyl ring family, but are lower than those of ABT-751, a representative of the pyridine family of colchicine site ligands. The three cell lines show similar responses to the compounds, but HT-29 is somewhat less sensitive to the more potent compounds in the series, a difference in sensitivity which has been previously observed for other colchicine site ligands [12,23].

Except for the oxadiazolines (**21**–**23**), which are all inactive, the different bridges connecting the two aromatic rings show small differences in cytotoxicity, with the oximes closely followed by the isocombretastatins and combretastatins, and the ketones showing lower potencies (e.g. compare **34**, **31**, **27** and **16** for the 4-methoxyphenyl series and **35**, **32**, **17** and **28** for the *N*-methylindole series), with the remarkable exception of ketone **39**, the most potent representative of the series. However, the nature of the bridge affects the relative potency of different B rings, thus suggesting different ring preferences for

Table 2

Cytotoxic activity against human cancer cell lines and Tubulin Polymerization Inhibitory Activity (TPI).



Comp	X	Z	Ar	R	IC ₅₀ Hela (μM) ^a	IC ₅₀ HL-60 (μM) ^a	IC ₅₀ HT-29 (μM) ^a	IC ₅₀ TPI (μM) ^b
13	OMe	Comb (Z + E)	3,4,5-TM	H	≥ 1	≥ 1	≥ 1	> 20
13E	OMe	Comb (E)	3,4,5-TM	H	≥ 1	≥ 1	≥ 1	> 20
14	OMe	Comb (Z + E)	4-MeO-Ph	H	1.00	–	≥ 1	> 20
14E	OMe	Comb (E)	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	> 20
15	OMe	Comb (Z + E)	2-Naphth	H	0.740	–	≥ 1	> 20
15E	OMe	Comb (E)	2-Naphth	H	≥ 1	≥ 1	≥ 1	> 20
16	SMe	Comb (Z)	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	4.1
17	SMe	Comb (Z)	1-MeIND	H	0.3 ± 0.09	0.4 ± 0.3	0.4 ± 0.02	1.0
21	SMe	Oxadiazole	4-(NMe ₂)Ph	H	≥ 1	≥ 1	≥ 1	> 5
22	SMe	Oxadiazole	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	> 5
23	SMe	Oxadiazole	1-MeIND	H	≥ 1	≥ 1	≥ 1	> 5
24	OMe	C=O	2-Naphth	H	≥ 1	≥ 1	≥ 1	> 5
25	OMe	C=O	1-MeIND	H	0.990	–	≥ 1	> 20
26	SMe	C=O	2-Naphth	H	0.7 ± 0.08	≥ 1	≥ 1	> 5
27	SMe	C=O	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	> 5
28	SMe	C=O	1-MeIND	H	0.1 ± 0.03	0.6 ± 0.04	≥ 1	> 5
29	SMe	C=O	4-(NMe ₂)Ph	H	0.6 ± 0.2	0.5 ± 0.2	≥ 1	> 5
30	OMe	C=CH ₂	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	> 5
31	SMe	C=CH ₂	4-MeO-Ph	H	0.5 ± 0.1	0.3 ± 0.01	≥ 1	4.1
32	SMe	C=CH ₂	1-MeIND	H	0.6 ± 0.1	0.3 ± 0.1	0.7 ± 0.1	> 5
33	SMe	C=CH ₂	4-(NMe ₂)Ph	H	0.5 ± 0.2	0.3 ± 0.02	≥ 1	> 5
34	SMe	C=NOH	4-MeO-Ph	H	0.2 ± 0.05	0.3 ± 0.04	0.2 ± 0.005	1.3
35	SMe	C=NOH	1-MeIND	H	0.2 ± 0.04	0.2 ± 0.03	≥ 1	1.6
36	SMe	C=NOH	4-(NMe ₂)Ph	H	0.6 ± 0.2	0.3 ± 0.1	≥ 1	> 5
37	SMe	CH-CH ₃	4-MeO-Ph	H	≥ 1	≥ 1	≥ 1	> 5
38	SMe	C=O	4-MeO-Ph	3-NO ₂	≥ 1	≥ 1	≥ 1	> 5
39	SMe	C=O	4-MeO-Ph	3-NH ₂	0.07 ± 0.013	0.06 ± 0.02	0.5 ± 0.01	0.9
40	SMe	C=O	1-MeIND	3-CHO	≥ 1	≥ 1	≥ 1	> 5
41	SMe	C=O	1-MeIND	3-CN	0.8 ± 0.005	0.2 ± 0.02	≥ 1	2.9
42	SMe	C=NOH	1-MeIND	3-CN	≥ 1	≥ 1	≥ 1	> 5
43	SMe	C=CH ₂	1-MeIND	3-CHO	0.4 ± 0.01	0.1 ± 0.005	0.7 ± 0.07	2.9
44	SMe	C=CH ₂	1-MeIND	3-COOH	≥ 1	≥ 1	≥ 1	> 5
45	SOMe	C=O	2-Naphth	H	≥ 1	≥ 1	≥ 1	> 5
46	SO ₂ Me	C=O	2-Naphth	H	≥ 1	≥ 1	≥ 1	> 5
47	SOMe	C=O	1-MeIND	H	≥ 1	≥ 1	≥ 1	> 5
48	SO ₂ Me	C=O	1-MeIND	H	≥ 1	≥ 1	≥ 1	> 5
CA4	–	–	–	–	0.003	0.013	0.032	1–3
ABT-751	–	–	–	–	0.388	–	0.514	–

^a Values are derived from concentration-response curves using the XTT assay as described in the Experimental Section. Data are shown as the mean values of three experiments performed in triplicate.

^b Tubulin polymerization inhibitory (TPI) IC₅₀.

bridges leading to different geometries. In isocombretastatins (1,1-diarylethenes) and oximes, there are small differences in potency between 4-methoxyphenyl, *N*-methyl-5-indolyl and 4-dimethylamino-phenyl (i.e. compare 31–33 and 34–36), whereas the *N*-methyl-5-indolyl is preferred over the 4-methoxyphenyl in combretastatins (1,2-diarylethenes) and phenstatins (benzophenones) (i.e. compare 16–17 and 27–28).

Oxidation of the methylsulfanyl group to the corresponding sulfones and sulfoxides leads to a complete potency loss (i.e. compare 45 and 46 with 24 and 47 and 48 with 28). Substitutions at the indole 3 position are neutral or detrimental for the activity and dependent on the nature of the bridge: a carbonyl is preferred over a hydrogen in isocombretastatins (i.e. compare 32 and 43) whereas in ketones a formyl group is detrimental and a cyano group is preferred (i.e. compare 28, 40 and 41), which is in turn detrimental in the oximes (i.e. compare 36 and 42). In the 4-methoxyphenyl series, substitution at the three position with a nitro group is detrimental but an amino group causes a potency increase of more than ten-fold down to double-digit nanomolar (i.e. compare 39 with 27).

2.2.2. Tubulin polymerization inhibition

We have applied a turbidimetric method to measure the effect of the compounds at concentrations between 5 and 20 μM on the total

polymer mass formed from bovine brain tubulin under *in vitro* assembly conditions (Table 2). For those compounds inhibiting tubulin polymerization more than 50% at 5 μM, we have determined the IC₅₀ values of microtubular protein polymerization inhibition (TPI). These values allowed us to compare the effects of the different compounds on the polymerization of tubulin and to the reference compounds combretastatin A-4 (one of the more potent tubulin polymerization inhibitors known with reported values between 1 and 3 μM) and ABT-751 (a representative of pyridine ligands with a TPI IC₅₀ of 2–4 μM), and to analyze the relationship between structure and TPI. The TPI results follow similar trends to the cytotoxicity results, thus suggesting an implication of tubulin polymerization inhibition in the action mechanism. The non-cytotoxic dimethoxypyridines and the oxadiazoles show TPIs higher than 5 μM. For the methylsulfanylpipridine derivatives, the only B rings leading to TPI IC₅₀s lower than 5 μM are the 4-methoxyphenyl and *N*-methyl-5-indolyl of the combretastatin (16 and 17), isocombretastatin (31 and 43), oxime (34 and 35), and ketone (39 and 41) series. For TPI, the oximes are the most potent (*ca* 1 μM), followed by combretastatins, with isocombretastatins and benzophenones showing progressively descending potencies. The most potent analogues show TPI values comparable to or better than the reference compounds. The 3-amino substituent of 39 causes a remarkable potency increase which parallels the observed effect on cytotoxicity (compare




Fig. 2. Effects of compounds **17** and **39** on the microtubule network and cell cycle in HeLa cells. Cells were incubated in the absence (Control) or in the presence of 1 μM of compounds **17** and **39** for 24 h, and then fixed and processed to analyze microtubules (red fluorescence) and nuclei (blue fluorescence) by confocal microscopy as described in the Experimental Section. Bar: 25 μm (control and **39**) and 50 μm (**17**). Cells were also analyzed in parallel by flow cytometry to determine their cell cycle profile. The photomicrographs and flow cytometry profiles shown are representative of three independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

39 with **27**) and therefore seems to be at the root of it. Also, in the benzophenone series, the introduction of a 3-cyano substituent on the *N*-methyl-5-indole results in a more moderate potency increase than for **39** but it is not accompanied by a similar increase in cytotoxic potency (compare **41** with **28**).

The most potent inhibitors of tubulin polymerization are also the most potent cytotoxic compounds and the only ones active against the HT-29 cell line with the only exception of **32**, thus suggesting that interference with tubulin polymerization is at the origin of the observed cellular effects. The cytotoxic 4-dimethylaminophenyl (**29**, **33** and **36**) and 2-naphthyl (**26**) analogues show TPI IC_{50} values higher than 5 μM with cytotoxicities comparable to more potent tubulin polymerization inhibitors such as **41** and **43**. This difference could be explained by an effect associated more with polymerization dynamics than with changes of polymer mass, as previously proposed.

2.2.3. Effects on cellular microtubules

The two compounds that showed the lowest IC_{50} for TPI, **17** (1.0 μM) and **39** (0.9 μM), promoted a drastic and severe disruption of the microtubule network in HeLa cells, as assessed by immunofluorescence confocal microscopy (Fig. 2). This microtubule disruption was accompanied by a cell cycle arrest at G_2/M phase (Fig. 2). These results further confirm that the above observed effects were due to interaction of compounds **17** and **39** with tubulin.

2.2.4. Effects on the cell cycle and induction of apoptosis

A dose-response and time-course analysis of the above synthesized compounds, showed that the most potent compounds, **17** and **39**, in promoting microtubule disruption and inhibition of cell proliferation (Table 2), led to cell cycle arrest at G_2/M followed by the induction of apoptosis, as assessed by the appearance of cells with sub- G_0/G_1 DNA content (Fig. 3).

Next, we carried out extensive dose-response and time-course analyses with the above microtubule-targeting compounds in different human cancer cells (Fig. 4). After 24 h incubation with HL-60, HeLa and HT-29 cells, compound **17** arrested most of the cells at the G_2/M phase (78.5%, 62.7% and 90.1% for HL-60, HeLa and HT-29, respectively) when used at only 100 nM (Fig. 4). Under these experimental conditions (100 nM, 24 h incubation), compound **39** arrested 66.6% and 54.4% of HL-60 and HeLa cells at G_2/M phase, respectively, whereas a higher concentration of **39** (1 μM) was required to arrest HT-29 cells at G_2/M phase (89.7%) after 24 h incubation (Fig. 4). At this time point, HeLa cells already showed significant apoptosis induction, as evidenced by a substantial number of cells (22.9% for **39** and 21.7% for **17**) at the sub- G_0/G_1 region. HL-60 and HT-29 showed a more delayed apoptotic response, which was evident at 48 h for compounds **17** (21.1% and 18.6% for HL-60 and HT-29 cells, respectively) and **39** (28.3% and 16.8% for HL-60 and HT-29 cells, respectively) at the indicated concentrations (Fig. 4). After 48 h, HeLa cells showed an increase in the sub- G_0/G_1 population (from 22.9% after 24 h to 36.8% after 48 h for **39**, and from 21.7% after 24 h to 24.7% after 48 h for **17**) accompanied by a reduction of the cells arrested at the G_2/M phase (from 54.4% after 24 h to 28.7% after 48 h for **39**, and from 62.7% after 24 h to 50.5% after 48 h for **17**) (Fig. 4). This trend continues for the three cell lines after 72 h (Fig. 4). These data suggest that the effects of **17** and **39** on microtubules disrupt microtubule polymerization, inducing a potent mitotic arrest that eventually triggers an apoptotic response, thus rendering a substantial cell demise in the drug-treated population.

2.3. Computational studies

The different effect of the methoxy and methylsulfanyl substituents at pyridine 6 position for matched molecular pairs of the synthesized compounds (e.g. on the TPI and cytotoxic potency) was investigated by means of DFT calculations in order to ascertain if they could be explained by their topological and/or electronic differences. The preferred conformation of the methoxy groups of the trimethoxyphenyl ring (Fig. 5) places the central methoxy group out of the plane of the phenyl ring due to steric hindrance with the *ortho* methoxy groups, which place their methyl carbons along the phenyl ring plane opposite to the central oxygen, due to steric hindrance as well. A second preferred conformation, 1.8 kcal/mol less stable, places the two lateral methoxy groups out of the ring plane with the central methoxy group protruding out of the plane of the phenyl ring on the opposite side. In the preferred conformation, the trimethoxyphenyl ring has its larger dimension along the ring plane in the 3–5 direction (methoxy carbon to methoxy carbon distance of 7.2 Å). For the 2,6-dimethoxyphenyls, the removal of the central methoxy group relieves the steric hindrance to the other methoxy groups, which orient themselves with their methyl groups towards the pyridine nitrogen. This results in a taller but less wide moiety (methoxy carbon to methoxy carbon distance of 4.5 Å). Rotation of one of the methoxy groups to place its methyl group *anti* to the pyridine nitrogen is very unfavorable (6.1 kcal/mol) due to the repulsive interactions of the lone pairs on the neighboring nitrogen and oxygen atoms. Substitution of one of the methoxy groups by a methylsulfanyl group results in a significant reduction of the penalty associated with the rotation of the carbon – sulfur bond to place the methyl *anti* to the nitrogen (1.4 kcal/mol), as the larger size of the sulfur atom reduces the repulsion between its lone pairs and that of the pyridine nitrogen. Furthermore, the longer carbon – sulfur bond lengths result in an almost complete recovery of the width of the




Fig. 3. Time-course and dose-response of the effects of compounds **17** and **39** on cell cycle in HeLa cells. Cells were incubated with different concentrations of **17** and **39** for the indicated times, and their DNA content was analyzed by fluorescence flow cytometry. The positions of the G₀/G₁ and G₂/M peaks are indicated by arrows, and the proportion of cells in each phase of the cell cycle was quantified by flow cytometry. The cell population in the sub-G₀/G₁ region represents cells with hypodiploid DNA content, an indicator of apoptosis. Untreated control cells were run in parallel. Data shown are representative of three independent experiments.

trimethoxyphenyl ring (methoxy carbon to methylsulfonyl carbon distance of 6.6 Å), thus explaining the recovery of the inhibitory activity. These results are in agreement with the observed disposition of the trimethoxyphenyl ring of different colchicine site analogues in complex with tubulin as determined by X-ray crystallographic studies (Fig. 5). Similar results are obtained for oxidations of the methylsulfonyl groups to the corresponding sulfoxide or sulfone (Fig. S1, Supplementary material), which preferentially place the oxygens of the sulfur atom *anti* to the pyridine nitrogen.

The binding mode of the synthesized compounds (Fig. 6) on tubulin has been investigated by docking experiments using 49 available X-ray crystal structures of tubulin in complex with different colchicine site ligands and 5 structures from molecular dynamics simulations, as previously described, in order to sample different protein configurations [23,28]. The proposed binding modes have been selected in a fully automated way as the optimal agreement of two docking programs with very different scoring functions (i.e. PLANTS [29] and AutoDock 4.2 [30]). For all the compounds assayed the preferred binding poses occupy the A (corresponding to the trimethoxyphenyl ring of combretastatin A-4) and B (corresponding to the 3-hydroxy-4-methoxyphenyl ring of combretastatin A-4) zones of the colchicine site [28,31]. The substituted pyridine rings occupy the A zone for all the compounds, except for compound **13**, which places the trimethoxyphenyl ring in this zone while the pyridine sits in zone B. The methoxy and methylsulfonyl substituents on the pyridine ring are placed at either side of the A site depending on the remainder of the structure, thus suggesting that its binding mode is more determined by the geometrical constraints of

the whole molecule rather than by an intrinsic preference of the substituents, in a similar way as observed for the SAR for the cytotoxic and TPI activities. The pyridine (A) ring is located in a hydrophobic pocket formed between helices H7 and H8, sheets S8 and S9 and the T7 loop, contacting with the sidechains of Ala316 β, Val318β, Leu248β, Ala354β, and Leu255β, with the pyridine nitrogen atom hydrogen bonding with the thiol group of Cys241β. The B rings are placed behind helix 8 and above sheets S8 and S9, thus providing a binding site more adapted to the docked virtual molecules. The optimal scores for the selected binding modes at each of these two proteins agreed better with the cytotoxicity or TPI ranking of the compounds than the overall best scores across all the protein sites, thus suggesting a more accurate comparison of the scores in a single site (Table S1, Suppl. Mat.). In any case, the inactive compounds **45** – **48** with oxidized methylsulfonyl groups (sulfones and sulfoxides) were scored as false positives, probably due to an inaccurate scoring of the sulfone and sulfoxide groups. The most potent compounds in cytotoxicity and TPI assays (i.e. **17** and **39**) were ranked afterwards, in good agreement with the experimental results.




Fig. 4. Effect of compounds **17** and **39** on the sub-G₀/G₁ and G₂/M cell cycle phases in HL-60, HeLa and HT-29 cells. Compounds were incubated for 24, 48 and 72 h, and then their DNA content was analyzed by flow cytometry as described in the Experimental Section. The different cell cycle phases were quantified and represented in column charts to easily visualize the changes in G₂/M arrest (■) and apoptotic response (■ sub-G₀/G₁). Untreated control cells were run in parallel, and the percentage of untreated cells in the sub-G₀/G₁ region was less than 3% in all the cell lines assayed. Data shown are representative of at least three independent experiments.

3. Conclusions

The replacement of the 3,4,5-trimethoxyphenyl by a 2-methoxy-6-methylsulfanyl-4-pyridyl moiety results in potent tubulin inhibition and

cytotoxicity against several human cancer cell lines and significantly improves the intrinsic aqueous solubility of colchicine site ligands with bridges of 2 (combretastatins) or 1 (isocombretastatins, phenstatins and oximes) sp² atoms. The effects of the other ring on potency vary with




Fig. 5. Structural comparison of the trimethoxyphenyl ring and the attempted substitutions: the 2,6-dimethoxy-4-pyridinyl and the 2-methoxy-6-methylsulfanyl-4-pyridinyl rings. The substituents are depicted in the 2D representation in the preferred dispositions. The different conformations are represented below in stick models looking at the rings from behind the central oxygen or the pyridine nitrogen along vertical axis and with a 90° counterclockwise rotation of the ring planes as depicted above. The distances from methyl carbon to methyl carbon and the relative energies in kcal/mol above the most stable (depicted in each case at the left most side) are indicated.

the nature of the bridge between the two aromatic rings, with a 3-amino-4-methoxyphenyl and a ketone bridge (**39**) providing the optimal combination of solubility and potency in the TPI and cytotoxicity assays. An indole ring also provides potent activity for the 1,2-

diarylethene series. Substitutions on the indole ring or oxidation of the methylsulfanyl groups abolishes the cytotoxicity. The more potent compounds displayed cytotoxicity against several human cancer cell lines due to tubulin inhibition, with complete G₂/M cell cycle arrest




Fig. 6. Structures of the compounds depicted in a–d. Proposed binding modes for compounds **39** (a and b) depicted with carbons in violet and **17** (c and d) depicted with carbons in orange, superposed onto the X-ray structure of combretastatin A-4 (a and c, carbons in pink) and a heterocyclic pyrimidine (b and d, carbons in green) in their complexes with tubulin. The colchicine binding domain is depicted in gray (pdb ID 5LYJ).

after 24 h followed by a high apoptosis-like cell response after 48–72 h. Molecular modelling studies support binding at the colchicine site and suggest binding of the pyridine moiety at the trimethoxyphenyl pocket of the colchicine site of tubulin and provide an explanation for the lack of activity of 2,6-dimethoxypyridine analogues and the potency increase observed for the 2-methoxy-6-methylsulfanylpriidine analogues. These compounds show improved aqueous solubility and therefore the structural modifications here described could be applied to improve colchicine site ligands.

4. Experimental section

4.1. Chemistry

4.1.1. General chemical techniques

Reagents were used as purchased without further purification. Solvents (THF, DMF, dichloromethane, and toluene) were dried and freshly distilled before use according to procedures described in the literature. TLC was performed on pre-coated silica gel polyester plates (0.25 mm thickness) with a UV fluorescence indicator 254 (Polychrom SI F254). Chromatographic separations were performed on silica gel columns by flash (Kieselgel 40, 0.040–0.063; Merck) or gravity (Kieselgel 60, 0.063–0.200 mm; Merck) chromatography. Melting points were determined on a Büchi 510 apparatus and are uncorrected. ^1H NMR and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker WP 200-SY spectrometer at 200/50 MHz or on a Bruker SY spectrometer at 400/100 MHz. Chemical shifts (δ) are given in ppm downfield from tetramethylsilane and coupling constants (J values) are in Hertz. IR spectra were run on a Nicolet Impact 410 Spectrophotometer. For FAB-HRMS analyses, a VG-TS250 apparatus (70 eV) was used. HPLCs were run on Waters X-Terra[®] MS C_{18} (5 mm, 4.6×150 mm) or C_8 (5 mm, 4.6×150 mm) with acetonitrile/water solvent gradients. All the compounds described here were obtained with at least 95% of purity by quantitative HPLC and/or elemental analysis, unless otherwise stated.

4.1.2. Chemical synthesis

4.1.2.1. General synthetic procedure for preparation of diarylketones (Procedure 1). 1 equivalent of $n\text{BuLi}$ (1.6 M in hexane) was added onto a solution of bromoderivative completely dissolved in dry THF at -40°C . After one hour stirring, 0.4 equivalents of carboxylic acid dissolved in dry THF was added and the mixture was warmed to room temperature. After 24 h, ethyl formate, ethyl acetate and water were added. The organic phase was partially evaporated, washed with brine, dried over Na_2SO_4 , filtered and evaporated to dryness. The products obtained were purified by flash chromatography.

4.1.2.2. General synthetic procedure for preparation of isocombretastatins (Procedure 2). A suspension of the phosphonium salt in dry THF was placed under stirring at -40°C and 0.67 equivalents of $n\text{BuLi}$ (1.6 M in hexane) were added. After one hour stirring, 0.33 equivalents of carbonyl compound dissolved in dry THF was added and the mixture was warmed to room temperature. Ammonium chloride and ethyl acetate were added 24 h later, and the organic phase was partially evaporated, washed with brine, dried over Na_2SO_4 , filtered and evaporated to dryness. The products obtained were purified by flash chromatography.

4.1.2.3. General synthetic procedure for preparation of oximes (Procedure 3). A solution of the carbonyl compound in methanol and 10 equivalents of hydroxylamine hydrochloride and 4 drops of pyridine were refluxed for 24 h. After that, solvent was evaporated and the product was dissolved in dichloromethane and washed with water. The organic phase was washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by flash chromatography obtaining the mixture of oximes (*E* and *Z*).

4.1.2.4. General synthetic procedure for preparation of oxadiazolines (Procedure 4). Hydrazide **12** was dissolved in a solution of $\text{EtOH}/\text{water}/\text{AcOH}$ (25:5:0.2) and 1 equivalent of aldehyde was added. After 24 h at 90°C , the product was extracted with ethyl acetate, washed with brine, dried over Na_2SO_4 and filtered. The acylhydrazones were purified by flash chromatography.

The acylhydrazones were dissolved in acetic anhydride and stirred at 160°C for one hour. The crude was poured onto ice and extracted with ethyl acetate, washed with sodium bicarbonate until basic pH, and then washed with brine. The organic phases were dried over Na_2SO_4 , filtered and evaporated to dryness under vacuum. The products were purified by flash chromatography.

4.1.2.5. General synthetic procedure for preparation of combretastatins (Procedure 5). 1.1 equivalents of $n\text{BuLi}$ (1.6 M in hexane) were added at -40°C to 1.2 equivalents of the corresponding phosphonium salt in dry THF. After one hour stirring, the corresponding aromatic aldehyde was slowly added and the reaction was progressively warmed to room temperature. After 72 h, the crude was poured onto ammonium chloride and extracted with ethyl acetate. The organic layers were washed with brine, dried over Na_2SO_4 , filtered and evaporated to dryness. Mixtures of *Z* and *E* isomers were obtained and separated by flash chromatography.

4.1.2.6. General synthetic procedure for preparation of aldehydes (Procedure 6). Phosphorus oxychloride (6 mmol per mmol of indole derivative) was added onto dry DMF at 0°C and stirred for half an hour. After that, indole derivative was added. Depending on the nature of the bridge, it was heated at 60°C for 2–24 h (phenstatins), or it was kept 2 h at room temperature (isocombretastatins). The solution was poured onto ice water with sodium acetate. After 24 h at 4°C , the precipitate was filtered, redissolved in dichloromethane, dried over anhydrous Na_2SO_4 , filtered and evaporated to dryness. The products were purified by flash chromatography.

4.1.2.7. General synthetic procedure for preparation of carbonitriles (Procedure 7). 10 equivalents of hydroxylamine hydrochloride and 4 drops of pyridine were added onto a solution of the corresponding aldehyde in methanol and refluxed for 24 h. After that, the solvent was evaporated and the product was dissolved in dichloromethane and washed with water. The organic phase was washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under vacuum.

Then, oximes were dissolved in pyridine and an excess of acetic anhydride was added, and stirred for 24–48 h at 130°C . The reaction was poured onto ice and subsequently extracted with dichloromethane, washed with 2 N HCl and then with 5% NaHCO_3 . The organic layers were washed with brine until neutral pH, dried over Na_2SO_4 , filtered and evaporated to dryness. The products were purified by flash chromatography.

4.1.2.8. 2,6-Dichloropyridine-4-carboxylic acid (1). 45.1 g of citrazinic acid (291 mmol) and 31 g of tetramethylammonium chloride (282.8 mmol) in POCl_3 (80 mL) were heated to 90°C until complete dissolution. Then, temperature was gradually increased to 140°C . After 24 h, the mixture was cooled to room temperature and poured on ice. The precipitate was filtered, washed with water and dried under vacuum. The solid was suspended in ethyl acetate, stirred for 15 min, and filtered to remove insoluble citrazinic acid. The organic solution was dried over Na_2SO_4 and evaporated, to obtain 42 g (218.8 mmol, 75.2%) of a brown solid corresponding to **1**. M.p. $203\text{--}204^\circ\text{C}$. IR (KBr): $2600\text{--}3300$, 1724 , 1596 , 1547 cm^{-1} . ^1H NMR (200 MHz, $\text{DMSO}-d_6$): 7.83 (2H, s), ^{13}C NMR (50 MHz, CD_3OD): 124.0 (2) (CH), 145.4 (C), 152.2 (2) (C), 165.0 (C).

4.1.2.9. 2-Chloro-6-methoxypyridine-4-carboxylic acid (2). 200 mL of a 25% solution of sodium methoxide in methanol was added on a solution

of 10.3 g (53.6 mmol) of 2,6-dichloropyridine-4-carboxylic acid (**1**) in 100 mL of methanol and refluxed for 24 h. The mixture was cooled to room temperature, filtered off and evaporated. The solid was dissolved in water, acidified with 2 N HCl and extracted with ethyl acetate. The organic phase was dried over anhydrous Na_2SO_4 , filtered and evaporated, to obtain 8.1 g (43.2 mmol, 81%) of 2-chloro-6-methoxypyridine-4-carboxylic acid (**2**) as a brown amorphous solid. ^1H NMR (200 MHz, CD_3OD): 3.87 (3H, s), 7.15 (1H, s), 7.36 (1H, s). ^{13}C NMR (50 MHz, CD_3OD): 54.5 (CH_3), 109.4 (CH), 115.5 (CH), 144.3 (C), 148.1 (C), 164.1 (C), 164.6 (C).

4.1.2.10. 2-Chloro-6-methylsulfanylpriidine-4-carboxylic acid (3). 50 mL of a solution of 3.84 g (54.8 mmol) of sodium methanethiolate in dry DMF was added onto a solution of 7 g (36.5 mmol) of 2,6-dichloropyridine-4-carboxylic acid (**1**) and 1 g of KOH in 100 mL of dry DMF and refluxed for 24 h. The mixture was cooled to room temperature, poured onto brine and extracted with ethyl acetate. The organic phase was washed with 2 N HCl and brine until neutral pH. The organic layer was dried over anhydrous Na_2SO_4 , filtered and evaporated, obtaining 6.71 g (32.9 mmol, 90.1%) of 2-chloro-6-methylsulfanylpriidine-4-carboxylic acid (**3**) as a brown amorphous solid. IR (film): 3100, 1706, 1588, 1545 cm^{-1} . ^1H NMR (200 MHz, CD_3OD): 2.46 (3H, s), 7.40 (1H, d, $J = 1$), 7.54 (1H, d, $J = 1$). ^{13}C NMR (50 MHz, CD_3OD): 13.7 (CH_3), 119.4 (CH), 120.3 (CH), 142.2 (C), 152.6 (C), 163.7 (C), 166.2 (C).

4.1.2.11. 2,6-Dimethoxypyridine-4-carboxylic acid (4). Acid **1** (4.75 g, 24.7 mmol) in diglyme was added on 60 mL of a MeONa/methanol solution. This mixture was refluxed in a Dean Stark apparatus for 24 h. The mixture was cooled to room temperature, filtered and evaporated. The solid was dissolved in water, acidified with 2 N HCl and extracted with ethyl acetate. The organic phase was dried over anhydrous Na_2SO_4 , filtered and evaporated, obtaining 3.01 g (164 mmol, 66.4%) of compound **4**. M.p. 222–225 °C ($\text{CH}_2\text{Cl}_2/\text{Hex}$). IR (film): 3354, 1704, 1619 cm^{-1} . ^1H NMR (200 MHz, CD_3OD): 3.82 (6H, s), 6.68 (2H, s). ^{13}C NMR (50 MHz, CD_3OD): 54.1 (2) (CH_3), 102.1 (2) (CH), 145.0 (C), 165.1 (2) (C), 167.8 (C).

4.1.2.12. 2-Methoxy-6-methylsulfanylpyridine-4-carboxylic acid (5). A saturated solution of sodium methoxide/methanol was added on 5.53 g (27.2 mmol) of 2-chloro-6-methylsulfanylpriidine-4-carboxylic acid in diglyme (50–100 mL) and refluxed for 24 h using a Dean-Stark trap. After reaction completion, the mixture was cooled to room temperature and diglyme was evaporated. The crude was dissolved in 2 N HCl and ethyl acetate, and organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered and evaporated, to obtain 5.10 g (25.6 mmol, 94%) of acid **5**. M.p. 178–179 °C (ethyl acetate). IR (film): 1703, 1597, 1557 cm^{-1} . ^1H NMR (200 MHz, CD_3OD): 2.47 (3H, s), 3.86 (3H, s), 6.81 (1H, s), 7.16 (1H, s). ^{13}C NMR (50 MHz, CD_3OD): 13.5 (CH_3), 54.3 (CH_3), 106.3 (CH), 113.7 (CH), 142.6 (C), 160.3 (C), 165.6 (C), 167.4 (C).

4.1.2.13. (2,6-Dimethoxypyridine-4-yl)-methanol (6). 16.4 g (89.6 mmol) of compound **4** in THF were cooled at 0 °C and 3.57 g of LiAlH_4 (89.3 mmol) were slowly added. After 1 h the reaction was allowed to reach room temperature. After 10 h, the reaction was poured onto ethyl acetate, filtered and evaporated to yield 10.9 g (64.4 mmol, 72%) of alcohol **6** as a white solid. M.p. 60–63 °C ($\text{CH}_2\text{Cl}_2/\text{Hex}$). IR (film): 3749, 1617, 1574 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 3.91 (6H, s); 4.63 (2H, s); 6.30 (2H, s). ^{13}C NMR (50 MHz, CDCl_3): 53.4 (CH_3), 63.3 (CH_2), 98.1 (2) (CH), 156.1 (2) (C), 163.3 (C). GC-MS m/z (relative intensity, %): 168 (100), 169 (M^+ , 77).

4.1.2.14. 2-Methoxy-6-(methylsulfanyl)pyridine-4-ylmethanol (7). 1.13 g (5.66 mmol) of acid **5** in THF were cooled at 0 °C and 0.32 g of LiAlH_4 (8.48 mmol) were slowly added. After 1 h the reaction was allowed to

reach room temperature and stirred for 10 h. The reaction was poured onto ethyl acetate, filtered and rotary evaporated to yield 0.88 g (4.72 mmol, 83%) of alcohol **7** as an oil. IR (film): 3347, 1598, 1559, cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.52 (3H, s), 3.91 (3H, s), 4.55 (2H, s), 6.35 (1H, s), 6.71 (1H, s). ^{13}C NMR (50 MHz, CDCl_3): 13.3 (CH_3), 53.5 (CH_3), 63.1 (CH_2), 102.3 (CH), 111.0 (CH), 153.4 (C), 157.4 (C), 163.3 (C).

4.1.2.15. 2,6-Dimethoxypyridine-4-carbaldehyde (8). 33.7 g (387.4 mmol) of MnO_2 were added to 10.9 g (64.5 mmol) of **6** in 500 mL of methanol and stirred for 72 h at room temperature. The crude was filtered off and the solvent was evaporated to yield 3.1 g (18 mmol, 28.8%) of **8**. M.p. (decomp) ($\text{CH}_2\text{Cl}_2/\text{Hex}$). ^1H NMR: 3.96 (6H, s), 6.71 (2H, s), 9.93 (1H, s). ^{13}C NMR: 54.0 (2) (CH_3), 100.7 (2) (CH), 147.5 (2) (C), 164.3 (C), 191.3 (CH). IR (film): 1711, 1570, 1458 cm^{-1} . GC-MS m/z (relative intensity, %): 166 (88), 167 (M^+ , 100).

4.1.2.16. 4-(Bromomethyl)-2-methoxy-6-(methylsulfanyl)pyridine (9). 0.88 g (4.72 mmol) of 2-methoxy-6-(methylsulfanyl)pyridine-4-ylmethanol (**7**) in 5 mL of acetic acid were cooled to 0 °C and 20 mL of HBr in acetic acid were slowly added. After 1 h the reaction was allowed to reach room temperature and stirred for 10 h. The reaction was poured onto ice and extracted with ethyl acetate. The organic layers were washed with 5% NaHCO_3 and brine, dried over anhydrous Na_2SO_4 , filtered and evaporated to yield 0.98 g (3.97 mmol, 84%) of alcohol 4-(bromomethyl)-2-methoxy-6-(methylsulfanyl)pyridine (**9**) as an oil. IR (film): 1601, 1559, 1456 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.53 (3H, s), 3.92 (3H, s), 4.98 (2H, s), 6.34 (1H, s), 6.70 (1H, s). ^{13}C NMR (50 MHz, CDCl_3): 12.9 (CH_3), 53.2 (CH_3), 64.0 (CH_2), 103.3 (CH), 111.5 (CH), 147.9 (C), 157.7 (C), 163.8 (C).

4.1.2.17. (2-Methoxy-6-(methylsulfanyl)pyridine-4-yl)methyltriphenylphosphonium bromide (10). 1.21 g (4.37 mmol) of PPh_3 were added to a solution of 0.98 g (3.97 mmol) of compound **9** in toluene. After 24 h, the crude was filtered to obtain 0.38 g (0.73 mmol, 19%) of compound **10** as a white solid. M.p. > 220 °C (Toluene). ^1H NMR (200 MHz, CDCl_3): 2.13 (3H, s), 3.78 (3H, s), 5.50 (2H, d, $J = 16.2$), 6.27 (1H, s), 6.54 (1H, s), 7.70 (15H, m).

4.1.2.18. 1-Methyl-1H-indole-5-carbaldehyde (11). 1.04 g (26 mmol) of NaOH and 20 mg of $n\text{-Bu}_4\text{NH}_4\text{SO}_4$ were added to a stirred solution of 1H-indole-5-carbaldehyde (2.0 g, 13.8 mmol) in 40 mL of dry dichloromethane. After 1 h at room temperature 3 mL (40.2 mmol) of methyl iodide were added and the reaction was heated at 50 °C. After 48 h, the reaction mixture was concentrated, re-dissolved in dichloromethane, washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuum to obtain 1.10 g (50.1%) of 1-methyl-1H-indole-5-carbaldehyde (**11**): M.p. 85–86 °C (ether). ^1H NMR (200 MHz, CDCl_3): 3.76 (3H, s), 6.55 (1H, d, $J = 3.3$), 7.10 (1H, d, $J = 3.3$), 7.41 (1H, d, $J = 8.8$), 7.80 (1H, dd, $J = 8.8$ and 1.9), 8.05 (1H, d, $J = 1.9$), 9.92 (1H, s). ^{13}C NMR (50 MHz, CDCl_3): 32.6 (CH_3), 103.1 (CH), 109.8 (CH), 121.4 (CH), 126.1 (CH), 128.2 (C), 129.1 (C), 130.9 (CH), 139.8 (C), 192.3 (CH).

4.1.2.19. 2-methylsulfanyl-6-methoxypyridinecarbohydrazide (12). A solution of 3.19 mL (65.8 mmol) of hydrazine in dichloromethane was added to 2.0 g (13.16 mmol) of compound **6**, 5.045 g (26.32 mmol) of EDCI, and 804 mg (6.48 mmol) of 4-DMAP in dichloromethane at room temperature. After 24 h, dichloromethane was evaporated, residue was dissolved in ethyl acetate and washed with 4% NaOH, 2 N HCl and brine, dried over anhydrous Na_2SO_4 , filtered and evaporated, to obtain 1.58 g (7.39 mmol, 56%) of compound **12** as a powder. IR (film): 3309, 1645, 1549 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.00 (2H, s), 2.51 (3H, s), 3.90 (3H, s), 6.68 (1H, d, $J = 1.1$), 7.05 (1H, d, $J = 1.1$), 7.89 (1H, s). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 53.9

(CH₃), 103.0 (CH), 110.9 (CH), 142.6 (C), 159.2 (C), 164.2 (C), 166.7 (C). HRMS (C₈H₁₁N₃O₂S): calcd 236.0464 (M + Na⁺), found 236.0468.

4.1.2.20. 2,6-dimethoxy-4-(3,4,5-trimethoxystyryl)-pyridine

(13). Prepared according to procedure 5: 27 mg (0.08 mmol, 2.9%) of 13(Z) and 15 mg (0.05 mmol, 1.9%) of 13(E).

(Z)-2,6-dimethoxy-4-(3,4,5-trimethoxystyryl)-pyridine (13): Oil. IR (film): 1609, 1152 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.69 (6H, s), 3.84 (3H, s), 3.85 (6H, s), 6.22 (2H, s), 6.41 (1H, d, *J* = 12.0), 6.48 (2H, s), 6.6 (1H, d, *J* = 12.0). ¹³C NMR (200 MHz, CDCl₃): 53.6 (2) (CH₃), 56.0 (2) (CH₃), 60.9 (CH₃), 100.9 (2) (CH), 106.3 (2) (CH), 127.6 (CH), 131.6 (C), 132.9 (CH), 150.6 (C), 152.9 (2) (C), 153.5 (C), 163.5 (2) (C). HRMS (C₁₈H₂₁NO₅): calcd 332.1492 (M + H⁺), found 332.1507.

(E)-2,6-dimethoxy-4-(3,4,5-trimethoxystyryl)-pyridine (13): Oil. IR (film): 1609, 1058 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.87 (3H, s); 3.91 (6H, s, OCH₃); 3.93 (6H, s); 6.40 (2H, s); 6.73 (2H, s); 6.84 (1H, d; *J* = 16.0); 7.13 (1H, d; *J* = 16.0). ¹³C NMR (50 MHz, CDCl₃): 53.6 (2) (CH₃); 56.2 (2) (CH₃); 61.0 (CH₃); 98.5 (2) (CH); 104.1 (2) (CH); 125.9 (CH); 132.1 (C); 132.5 (CH); 149.9 (C); 153.5 (2) (C); 155.1 (C); 163.8 (2) (C). HRMS (C₁₈H₂₁NO₅): calcd 332.1492 (M + H⁺), found 332.1505.

4.1.2.21. 2,6-dimethoxy-4-(4-methoxystyryl)-pyridine (14). Prepared according to procedure 5: 286 mg (1.05 mmol, 29.2%) of 14(Z) and 119 mg (0.44 mmol, 12.2%) of 14(E).

(Z)-2,6-dimethoxy-4-(4-methoxystyryl)-pyridine (14): Oil. IR (film): 1608, 1511 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.78 (3H, s), 3.85 (6H, s), 6.19 (2H, s), 6.33 (1H, d, *J* = 12.0), 6.62 (1H, d, *J* = 12.0), 6.76 (2H, d, *J* = 9.0), 7.18 (2H, d, *J* = 9.0). ¹³C NMR (200 MHz, CDCl₃): 53.4 (2) (CH₃), 55.1 (CH₃), 100.9 (2) (CH), 113.7 (2) (CH), 126.4 (CH), 128.8 (C), 130.3 (2) (CH), 132.7 (CH), 150.8 (C), 159.2 (C), 163.5 (2) (C). HRMS (C₁₆H₁₇NO₃): calcd 272.1281 (M + H⁺), found 272.1283.

(E)-2,6-dimethoxy-4-(4-methoxystyryl)-pyridine (14): Oil. IR (film): 1606 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.82 (3H, s), 3.93 (6H, s), 6.39 (2H, s), 6.80 (1H, d, *J* = 16.0), 6.89 (2H, d, *J* = 8.0); 7.16 (2H, d, *J* = 16.0), 7.45 (2H, d, *J* = 8.0). ¹³C NMR (50 MHz, CDCl₃): 53.5 (2) (CH₃), 55.3 (CH₃), 98.3 (2) (CH), 114.2 (2) (CH), 124.2 (CH), 128.4 (2) (CH), 129.1 (C), 132.1 (CH), 150.4 (C), 160.0 (C), 163.8 (2) (C). HRMS (C₁₆H₁₇NO₃): calcd 272.1281 (M + H⁺), found 272.1289.

4.1.2.22. 2,6-dimethoxy-4-(2-naphth-2-ylvinyl)-pyridine (15). Prepared according to procedure 5: 80 mg (0.27 mmol, 7.5%) of 15(Z) and 140 mg (0.48 mmol, 13.3%) of 15(E).

(Z)-2,6-dimethoxy-4-(2-naphth-2-ylvinyl)-pyridine (15): Oil. IR (film): 1609, 1553 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.82 (6H, s), 6.20 (2H, s), 6.52 (1H, d, *J* = 12.0), 6.86 (1H, d, *J* = 12.0); 7.3–7.8 (7H, m). ¹³C NMR (200 MHz, CDCl₃): 53.5 (2) (CH₃), 100.9 (2) (CH), 126.2 (2) (CH), 126.7 (CH), 127.7 (2) (CH), 128.1 (CH), 128.4 (2) (CH), 132.7(C), 132.8 (C), 133.2 (CH), 133.9 (C), 150.4 (C), 163.5 (2) (C). HRMS (C₁₆H₁₇NO₃): calcd 292.1332 (M + H⁺), found 292.1341.

(E)-2,6-dimethoxy-4-(2-naphth-2-ylvinyl)-pyridine (15): Oil. IR (film): 1550, 1607 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 3.96 (6H, s), 6.47 (2H, s), 7.07 (1H, d, *J* = 16.0), 7.38 (1H, d, *J* = 16.0), 7.40–7.90 (7H, m). ¹³C NMR (50 MHz, CDCl₃): 53.6 (2) (CH₃), 98.6 (2) (CH), 123.5 (2) (CH), 126.4 (CH), 126.8 (CH), 127.8 (2) (CH), 128.2 (CH), 128.5 (CH), 132.6 (CH), 133.5 (C), 133.6 (C), 133.9 (C), 150.0 (C), 163.8 (2) (C). HRMS (C₁₆H₁₇NO₃): calcd 292.1332 (M + H⁺), found 292.1335.

4.1.2.23. 2-methoxy-4-(4-methoxystyryl)-6-(methylsulfanyl)pyridine

(16). Prepared according to procedure 5: 11 mg (0.04 mmol, 10%) of 16(Z) as an oil and 43 mg (0.15 mmol, 40%) of a 1:1 mixture of 16(Z + E). IR (film): 1587, 1538 cm⁻¹. ¹H NMR (200 MHz, CDCl₃, Z Isomer): 2.45 (3H, s), 3.79 (3H, s), 3.89 (3H, s), 6.28 (1H, d, *J* = 12.0),

6.29 (1H, s), 6.62 (1H, d, *J* = 12.0), 6.63 (1H, s), 6.77 (2H, d, *J* = 8.9), 7.17 (2H, d, *J* = 8.9). ¹³C NMR (50 MHz, CDCl₃, Z + E Isomers): 13.4 (CH₃), 53.5 (CH₃), 5.4 (CH₃), 102.6 (CH), 105.0 (CH), 111.0 (CH), 113.4 (CH), 113.8 (2) (CH), 114.3 (2) (CH), 123.8 (CH), 125.9 (CH), 128.4 (2) (CH), 129.0 (C), 130.3 (2) (CH), 132.5 (CH), 133.2 (CH), 148.0 (C), 148.5 (C), 157.4 (C), 159.2 (C), 160.1 (C), 164.4 (C). HRMS (C₁₆H₁₇NO₂S): calcd 310.0872 (M + Na⁺), found 310.0874. HPLC (Z Isomer): C₈ t_R: 20.74 min.

4.1.2.24. 5-(2-(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)vinyl)-1-methyl-1H-indole

(17). Prepared according to procedure 5: 4.5 mg (0.01 mmol, 4%) of 17(Z) as an oil, and 17 mg (0.05 mmol, 16%) of a 1:1 mixture of 17(Z + E). IR (film): 1587, 1541 cm⁻¹. ¹H NMR (200 MHz, CDCl₃, Z Isomer): 2.41 (3H, s), 3.77 (3H, s), 3.87 (3H, s), 6.30 (1H, d, *J* = 12.0), 6.41 (1H, d, *J* = 3.2), 6.69 (1H, s), 6.78 (1H, s), 6.84 (1H, d, *J* = 12.0), 7.02 (1H, d, *J* = 3.2), 7.15 (1H, d, *J* = 8.6), 7.17 (1H, d, *J* = 8.6), 7.53 (1H, s). ¹³C NMR (50 MHz, CDCl₃, Z + E Isomers): 13.3 (CH₃), 32.0 (CH₃), 53.4 (CH₃), 101.4 (CH), 101.6 (CH), 102.4 (CH), 103.5 (CH), 105.1 (CH), 108.9 (CH), 109.5 (CH), 111.0 (CH), 111.8 (CH), 113.5 (CH), 120.4 (CH), 120.6 (CH), 121.7 (CH), 122.7 (CH), 122.9 (CH), 125.0 (CH), 127.3 (C), 127.8 (C), 128.7 (C), 129.3 (CH), 129.6 (CH), 134.4 (CH), 135.1 (CH), 148.4 (C), 164.0 (C), 164.3 (C). HRMS (C₁₈H₁₈N₂OS): calcd 311.1212 (M + H⁺), found 311.1206. HPLC (Z isomer): C₁₈ t_R: 24.04 min.

4.1.2.25. 2,6-dimethoxy-4-(3,4,5-trimethoxyphenethyl)-pyridine

(18). 3 mg of 5% Pd(C) were added to 25 mg of 2,6-dimethoxy-4-(3,4,5-trimethoxystyryl)-pyridine (13) in 20 mL of ethanol under H₂ atmosphere. After 18 h, the reaction was filtered through celite® and evaporated to yield 20 mg (0.06 mmol, 75%) of 2,6-dimethoxy-4-(3,4,5-trimethoxyphenethyl)-pyridine (18) as an oil. IR (film): 1612, 1566 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 2.81 (4H, s); 3.81 (9H, s); 3.88 (6H, s), 6.14 (2H, s), 6.37 (2H, s). ¹³C NMR (50 MHz, CDCl₃): 36.9 (CH₂), 37.2 (CH₂), 53.5 (2) (CH₃), 56.1 (2) (CH₃), 60.9 (CH₃), 101.1 (2) (CH), 105.4 (2) (CH), 136.9 (C), 153.2 (2) (C), 156.0 (C), 163.4 (2) (C). HRMS (C₁₈H₂₃NO₅): calcd 334.1648 (M + H⁺), found 334.1658.

4.1.2.26. 2,6-dimethoxy-4-(4-methoxyphenethyl)-pyridine (19). 15 mg of 5% Pd(C) were added to 200 mg of 2,6-dimethoxy-4-(4-methoxystyryl)-pyridine (14) in 20 mL of ethanol under H₂ atmosphere. After 18 h, the reaction was filtered through celite® and evaporated to yield 184 mg (0.67 mmol, 91%) of 2,6-dimethoxy-4-(4-methoxyphenethyl)-pyridine (19) as an oil. IR (film): 1619, 1513 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 2.80–2.82 (4H, m), 3.76 (3H, s), 3.89 (6H, s), 6.14 (2H, s), 6.81 (2H, d, *J* = 8.6), 7.08 (2H, d, *J* = 8.6). ¹³C NMR (50 MHz, CDCl₃): 35.6 (CH₂), 37.4 (CH₂), 53.4 (2) (CH₃), 55.2 (CH₃), 101.1 (2) (CH), 113.8 (2) (CH), 129.3 (2) (CH), 133.2 (C), 156.3 (C), 158.0 (C), 163.3 (2) (C). HRMS (C₁₆H₂₁NO₃): calcd 274.1438 (M + H⁺), found 274.1451.

4.1.2.27. 2,6-dimethoxy-4-(2-(naphth-2-yl)ethyl)-pyridine (20). 8 mg of 5% Pd(C) were added to 100 mg (0.34 mmol) of 2,6-dimethoxy-4-(2-naphth-2-ylvinyl)-pyridine (15) in 35 mL of ethanol H₂ atmosphere. After 16 h, the reaction was filtered through celite® and evaporated to yield 83 mg (0.28 mmol, 82%) of 2,6-dimethoxy-4-(2-(naphth-2-yl)ethyl)-pyridine (20) as an oil. IR (film): 1566 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 2.94–3.12 (4H, m), 3.91 (6H, s), 6.21(2H, s), 7.31–7.81 (7H, m). ¹³C NMR (50 MHz, CDCl₃): 36.7 (CH₂), 37.1 (CH₂), 53.5 (2) (CH₃), 101.1 (CH), 125.4 (CH), 126.0 (CH), 126.5 (CH), 127.2 (CH), 127.6 (CH), 127.7 (CH), 128.1 (CH), 132.2 (C), 133.7 (C), 138.7 (C), 156.1 (C), 163.4 (2) (C). HRMS (C₁₉H₂₀NO₂): calcd 294.1488 (M + H⁺), found 294.1498.

4.1.2.28. 1-(2-(4-(dimethylamino)phenyl)-5-(2-methoxy-6-

(methylsulfanyl)pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (21). Prepared according to procedure 4: 82 mg (0.21 mmol, 32%).

Oil. IR (film): 1603, 1550 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.34 (3H, s), 2.57 (3H, s), 2.96 (6H, s), 3.97 (3H, s), 6.69 (2H, d, $J = 8.6$), 6.82 (1H, d, $J = 0.7$), 7.00 (1H, s), 7.20 (1H, d, $J = 0.7$), 7.29 (2H, d, $J = 8.6$). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 21.6 (CH_3), 40.4 (2) (CH_3), 53.9 (CH_3), 93.6 (CH), 102.8 (CH), 110.5 (CH), 112.2 (2) (CH), 123.2 (C), 127.7 (2) (CH), 135.1 (C), 151.6 (C), 153.8 (C), 158.8 (C), 164.1 (C), 167.8 (C). HRMS ($\text{C}_{19}\text{H}_{22}\text{N}_4\text{O}_3\text{S}$): calcd 409.1304 ($\text{M} + \text{Na}^+$), found 409.1320. HPLC: C_8 t_R : 4.032 min.

4.1.2.29. 1-(5-(2-methoxy-6-(methylthio)pyridin-4-yl)-2-(4-methoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (22). Prepared according to procedure 4: 118 mg (0.32 mmol, 96%). Amorphous powder. IR (KBr): 1665, 1610, 1555 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.34 (3H, s), 2.57 (3H, s), 3.79 (3H, s), 3.97 (3H, s), 6.81 (1H, d, $J = 1.1$), 6.90 (2H, d, $J = 8.6$), 7.02 (1H, s), 7.19 (1H, d, $J = 1.1$), 7.37 (2H, d, $J = 8.6$). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 21.5 (CH_3), 53.9 (CH_3), 55.4 (CH_3), 93.0 (CH), 102.8 (CH), 110.4 (CH), 114.3 (2) (CH), 128.1 (2) (CH), 128.3 (C), 134.9 (C), 153.8 (C), 158.9 (C), 160.9 (C), 164.1 (C), 167.9 (C). HRMS ($\text{C}_{18}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$): calcd 396.0988 ($\text{M} + \text{Na}^+$), found 396.0987. HPLC: C_8 t_R : 20.59 min.

4.1.2.30. 1-(5-(2-methoxy-6-(methylthio)pyridin-4-yl)-2-(1-methyl-1H-indol-5-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (23). Prepared according to procedure 4: 133 mg (0.34 mmol, 46%). Amorphous powder. IR (film): 1672, 1625, 1596 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.38 (3H, s), 2.58 (3H, s), 3.76 (3H, s), 3.97 (3H, s), 6.49 (1H, d, $J = 3.2$), 6.85 (1H, s), 7.07 (1H, d, $J = 3.2$), 7.19 (1H, s), 7.23 (1H, s), 7.30 (2H, bd), 7.72 (1H, bs). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 21.6 (CH_3), 32.9 (CH_3), 53.9 (CH_3), 94.3 (CH), 101.7 (CH), 102.8 (CH), 109.8 (CH), 110.5 (CH), 119.8 (2) (CH), 127.1 (C), 128.4 (C), 130.0 (CH), 135.1 (C), 137.6 (C), 153.8 (C), 158.9 (C), 164.1 (C), 167.8 (C). HRMS ($\text{C}_{20}\text{H}_{20}\text{N}_4\text{O}_3\text{S}$): calcd 419.1148 ($\text{M} + \text{Na}^+$), found 419.1160. HPLC: C_8 t_R : 21.04 min. C_{18} t_R : 22.60 min.

4.1.2.31. (2,6-dimethoxypyridin-4-yl)(naphthalen-2-yl)methanone (24). Prepared according to procedure 1: 31 mg, 0.10 mmol, 38%). Amorphous powder. IR (film): 1662, 1562 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 4.00 (6H, s), 6.62 (2H, s), 7.5–7.7 (3H, m), 7.9–8.0 (3H, m), 8.29 (1H, bs). ^{13}C NMR (50 MHz, CDCl_3): 53.9 (2) (CH_3), 101.1 (2) (CH), 125.1 (CH), 126.9 (CH), 127.8 (CH), 128.5 (CH), 128.8 (CH), 129.6 (CH), 132.1 (C), 132.6 (CH), 133.3 (C), 135.6 (C), 150.5 (C), 163.4 (2) (C), 195.2 (C). HRMS ($\text{C}_{18}\text{H}_{15}\text{NO}_3$): calcd 294.1124 ($\text{M} + \text{H}^+$), found 294.1138. HPLC: C_{18} t_R : 23.61 min.

4.1.2.32. (2,6-dimethoxypyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (25). 3.9 mL of $n\text{BuLi}$ 1.6 M in hexane (6.2 mmol) were added to a solution 685 mg (3.3 mmol) of 5-bromo-N-methyl-1H-indole in 50 mL of dry THF at -40°C . After 1 h, 519 mg (3.1 mmol) of 2,6-dimethoxypyridin-4-carbaldehyde dissolved in 20 mL of dry THF were slowly added over 1 h and then allowed to reach room temperature. After 24 h the reaction was poured onto ethyl acetate and evaporated. The residue was dissolved in 20 mL of dry dichloromethane and 100 mg (6.3 mol) of KMnO_4 and 2 mg of tetrabutylammonium hydrogen sulfate were added and stirred for 24 h at room temperature. The crude was flash chromatographed using Hexane/ethyl acetate 1:1 to give 150 mg (0.5 mmol, 16%) of (2,6-dimethoxypyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (25). Amorphous powder. IR (film): 1654, 1560 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 3.84 (3H, s), 3.97 (6H, s), 6.57 (1H, m), 6.58 (2H, s), 7.13 (1H, d, $J = 3.0$), 7.38 (1H, d, $J = 9.0$), 7.86 (1H, dd, $J = 1.8$, $J = 9.0$), 8.13 (1H, d, $J = 1.8$). ^{13}C NMR (50 MHz, CDCl_3): 33.1 (CH_3), 53.9 (2) (CH_3), 101.1 (2) (CH), 103.3 (CH), 109.4 (CH), 123.6 (CH), 125.9 (CH), 127.8 (2) (C), 130.7 (CH), 139.4 (C), 152.1 (C), 163.3 (2) (C), 195.5 (C). HRMS ($\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_3$): calcd 297.1233 ($\text{M} + \text{H}^+$), found 297.1241.

4.1.2.33. (2-methoxy-6-(methylsulfanyl)pyridin-4-yl)(naphthalen-2-yl)

methanone (26). Prepared according to procedure 1: 329 mg (1.1 mmol, 24%). M.p. $76\text{--}77^\circ\text{C}$ (Et_2O). IR (KBr): 1657, 1589 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.61 (3H, s), 4.02 (3H, s), 6.70 (1H, d, $J = 1.1$), 7.08 (1H, d, $J = 1.1$), 7.5–7.7 (3H, m), 7.8–8.0 (3H, m), 8.2 (1H, bs). ^{13}C NMR (50 MHz, CDCl_3): 13.6 (CH_3), 53.9 (CH_3), 105.5 (CH), 112.9 (CH), 125.2 (CH), 126.0 (CH), 127.9 (CH), 128.5 (CH), 129.0 (CH), 129.7 (CH), 132.2 (C), 133.3 (C), 132.7 (CH), 136.7 (C), 148.1 (C), 158.8 (C), 163.9 (C), 195.0 (C). HRMS ($\text{C}_{18}\text{H}_{15}\text{NO}_2\text{S}$): calcd 310.0896 ($\text{M} + \text{H}^+$), found 310.0911. HPLC: C_8 t_R : 21.79 min. C_{18} t_R : 23.58 min.

4.1.2.34. (2-methoxy-6-(methylsulfanyl)pyridin-4-yl)(4-methoxyphenyl)methanone (27). Prepared according to procedure 1: 372 mg (1.28 mmol, 51%). M.p. 62°C ($\text{Hex}/\text{CH}_2\text{Cl}_2$). IR (KBr): 1659, 1545 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.59 (3H, s), 3.89 (3H, s), 3.99 (3H, s), 6.61 (1H, d, $J = 1.1$), 6.95 (2H, d, $J = 8.6$), 6.97 (1H, d, $J = 1.1$), 7.83 (2H, d, $J = 8.6$). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 53.8 (CH_3), 55.6 (CH_3), 105.1 (CH), 112.6 (CH), 113.9 (2) (CH), 115.5 (C), 128.6 (C), 132.6 (2) (CH), 148.5 (C), 158.5 (C), 163.9 (C), 193.5 (C). HRMS ($\text{C}_{15}\text{H}_{15}\text{NO}_3\text{S}$): calcd 290.0845 ($\text{M} + \text{H}^+$), found 290.0849. HPLC: C_{18} t_R : 22.04 min.

4.1.2.35. (2-methoxy-6-(methylsulfanyl)pyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (28). Prepared according to procedure 1: 911 mg (2.92 mmol, 49%). M.p. $103\text{--}104^\circ\text{C}$ ($\text{Hex}/\text{CH}_2\text{Cl}_2$). IR: 1647, 1545 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.49 (3H, s), 3.85 (3H, s), 4.01 (3H, s), 6.59 (1H, d, $J = 2.9$), 6.66 (1H, d, $J = 1.1$), 7.02 (1H, d, $J = 1.1$), 7.13 (1H, d, $J = 2.9$), 7.38 (1H, d, $J = 8.6$), 7.81 (1H, dd, $J = 8.6$, $J = 1.8$), 8.10 (1H, d, $J = 1.8$). ^{13}C NMR (50 MHz, CDCl_3): 13.5 (CH_3), 33.1 (CH_3), 53.9 (CH_3), 103.3 (CH), 105.3 (CH), 109.5 (CH), 112.9 (CH), 123.4 (CH), 125.8 (CH), 127.7 (C), 128.8 (C), 130.9 (CH), 139.4 (C), 149.6 (C), 158.3 (C), 163.7 (C), 195.2 (C). HRMS ($\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2\text{S}$): calcd 313.1005 ($\text{M} + \text{H}^+$), found 313.1013. HPLC: C_{18} t_R : 20.85 min.

4.1.2.36. (4-(dimethylamino)phenyl)(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)methanone (29). Prepared according to procedure 1: 723 mg (2.39 mmol, 41%). Foam. IR (KBr): 1644, 1543 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.58 (3H, s), 3.09 (6H, s), 3.98 (3H, s), 6.59 (1H, d, $J = 1.1$), 6.67 (2H, d, $J = 9.1$), 6.95 (1H, d, $J = 1.1$), 7.77 (2H, d, $J = 9.1$). ^{13}C NMR (50 MHz, CDCl_3): 13.5 (CH_3), 40.1 (2) (CH_3), 53.8 (CH_3), 104.9 (CH), 110.6 (2) (CH), 115.6 (CH), 123.2 (C), 132.7 (2) (CH), 149.8 (C), 153.8 (C), 158.1 (C), 163.7 (C), 192.8 (C). HRMS ($\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$): calcd 303.1161 ($\text{M} + \text{H}^+$), found 303.1154. HPLC: C_8 t_R : 19.04 min.

4.1.2.37. 2,6-dimethoxy-4-(1-(4-methoxyphenyl)vinyl)pyridine (30). Prepared according to procedure 2: 4 mg (0.015 mmol, 0.8%). Oil. IR (film): 1609, 1554 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 3.83 (3H, s), 3.91 (6H, s), 5.43 (1H, s), 5.45 (1H, s), 6.27 (2H, s), 6.86 (2H, d, $J = 8.6$), 7.24 (2H, d, $J = 8.6$). ^{13}C NMR (50 MHz, CDCl_3): 53.6 (2) (CH_3), 55.3 (CH_3), 100.7 (2) (CH), 113.6 (2) (CH), 114.6 (CH_2), 129.2 (2) (CH), 132.5 (C), 147.6 (C), 159.2 (C), 159.5 (C), 163.2 (2) (C). HRMS ($\text{C}_{16}\text{H}_{17}\text{NO}_3$): calcd 272.1281 ($\text{M} + \text{H}^+$), found 272.1293. HPLC: C_{18} t_R : 22.57 min.

4.1.2.38. 2-methoxy-4-(1-(4-methoxyphenyl)vinyl)-6-(methylsulfanyl)pyridine (31). Prepared according to procedure 2: 95 mg (0.33 mmol, 49%). Oil. IR (film): 1594, 1518 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.56 (3H, s), 3.82 (3H, s), 3.96 (3H, s), 5.43 (1H, d, $J = 1.4$), 5.47 (1H, d, $J = 1.4$), 6.38 (1H, d, $J = 1.4$), 6.74 (1H, d, $J = 1.4$), 6.86 (2H, d, $J = 8.9$), 7.23 (2H, d, $J = 8.9$). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 53.6 (CH_3), 55.3 (CH_3), 105.0 (CH), 113.4 (CH), 113.7 (2) (CH), 115.0 (CH_2), 129.3 (2) (CH), 132.3 (C), 147.3 (C), 152.5 (C), 157.1 (C), 159.6 (C), 164.1 (C). HRMS ($\text{C}_{16}\text{H}_{17}\text{NO}_2\text{S}$): calcd 288.1052 ($\text{M} + \text{H}^+$), found 288.1068. HPLC: C_{18} t_R : 23.89 min.

4.1.2.39. 5-(1-(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)vinyl)-1-methyl-1H-indole (32). Prepared according to procedure 2: 30 mg (0.10 mmol, 31%). Oil. IR (film): 1593, 1543 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.56 (3H, s), 3.80 (3H, s), 3.96 (3H, s), 5.48 (1H, d, $J = 1.1$), 5.54 (1H, d, $J = 1.1$), 6.44 (1H, d, $J = 1.2$), 6.47 (1H, bd, $J = 3.2$), 6.79 (1H, d, $J = 1.2$), 7.06 (1H, d, $J = 3.2$), 7.18 (1H, dd, $J = 1.4$, $J = 8.9$), 7.28 (1H, d, $J = 8.9$), 7.55 (1H, d, $J = 1.4$). ^{13}C NMR (50 MHz, CDCl_3): 13.4 (CH_3), 33.0 (CH_3), 53.6 (CH_3), 101.4 (CH), 105.1 (CH), 109.0 (CH), 113.7 (CH), 114.9 (CH_2), 120.8 (CH), 122.1 (CH), 128.0 (C), 136.6 (CH), 131.3 (C), 136.6 (C), 148.9 (C), 153.3 (C), 156.9 (C), 164.0 (C). HRMS ($\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$): calcd 311.1212 ($\text{M} + \text{H}^+$), found 312.1219. HPLC: C_8 t_R : 22.01 min.

4.1.2.40. 4-(1-(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)vinyl)-N,N-dimethylaniline (33). Prepared according to procedure 2: 90 mg (0.30 mmol, 33%). Oil. IR (film): 1592, 1532 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.56 (3H, s), 2.98 (6H, s), 3.95 (3H, s), 5.32 (1H, d, $J = 1.1$), 5.44 (1H, d, $J = 1.1$), 6.40 (1H, d, $J = 1.1$), 6.72 (2H, d, $J = 8.9$), 6.76 (1H, d, $J = 1.1$), 7.19 (2H, d, $J = 8.9$). ^{13}C NMR (50 MHz, CDCl_3): 13.5 (CH_3), 40.5 (2) (CH_3), 53.6 (CH_3), 105.1 (CH), 110.6 (CH), 112.1 (2) (CH), 113.9 (CH_2), 128.8 (2) (CH), 132.8 (C), 147.7 (C), 150.3 (C), 153.1 (C), 156.9 (C), 164.0 (C). HRMS ($\text{C}_{17}\text{H}_{20}\text{N}_2\text{OS}$): calcd 301.1369 ($\text{M} + \text{H}^+$), found 301.1351. HPLC: C_8 t_R : 22.3 min.

4.1.2.41. Oximes of (2-methoxy-6-(methylsulfanyl)pyridin-4-yl)(4-methoxyphenyl)methanone (34). Prepared according to procedure 3: 105 mg (0.35 mmol, 27%) of **34(E)**, 66 mg (0.22 mmol, 17%) of **34(Z)**, and 108 mg (0.27 mmol, 21%) of a 1:1 mixture of **34(Z + E)**. **34(E)**: M.p. 92–93 °C ($\text{Hex}/\text{CH}_2\text{Cl}_2$). IR (KBr): 3272, 3203, 1598, 1544 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.53 (3H, s), 3.85 (3H, s), 3.94 (3H, s), 6.46 (1H, d, $J = 1.1$), 6.88 (1H, d, $J = 1.1$), 6.96 (2H, d, $J = 8.9$), 7.38 (2H, d, $J = 8.9$). **34(Z)**: ^1H NMR (200 MHz, CDCl_3): 2.56 (3H, s), 3.80 (3H, s), 3.97 (3H, s), 6.42 (1H, d, $J = 1.1$), 6.75 (1H, d, $J = 1.1$), 6.84 (2H, d, $J = 8.9$), 7.38 (2H, d, $J = 8.9$). ^{13}C NMR (50 MHz, CDCl_3 , $\text{Z} + \text{E}$ Isomers): 13.4 (CH_3), 53.7 (CH_3), 55.4 (CH_3), 104.8 (CH), 105.5 (CH), 112.4 (CH), 113.3 (CH), 113.7 (2) (CH), 114.0 (2) (CH), 123.3 (C), 126.9 (C), 128.9 (2) (CH), 131.2 (2) (CH), 132.8 (C), 143.9 (C), 147.2 (C), 155.5 (C), 155.6 (C), 157.8 (C), 158.1 (C), 160.4 (C), 161.0 (C), 163.9 (C). HRMS ($\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$): calcd 305.0954 ($\text{M} + \text{H}^+$), found 305.0962. HPLC: C_{18} t_R : 19.89 min, t_R : 20.25 min.

4.1.2.42. Oximes of (2-methoxy-6-(methylsulfanyl)pyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (35). Prepared according to procedure 3: 228 mg (0.70 mmol, 70%) of **35(E)** was isolated, but it isomerized to regenerate the original mixture of isomers (4:6). M.p. 155–157 °C ($\text{Hex}/\text{CH}_2\text{Cl}_2$). IR (KBr): 3272, 3227, 1589 cm^{-1} . ^1H NMR (200 MHz, CDCl_3 , E Isomer): 2.53 (3H, s), 3.83 (3H, s), 3.92 (3H, s), 6.48 (1H, d, $J = 1.1$), 6.53 (1H, d, $J = 3.2$), 6.93 (1H, d, $J = 1.1$), 7.11 (1H, d, $J = 3.2$), 7.25 (1H, dd, $J = 1.4$, $J = 8.4$), 7.39 (1H, bd, $J = 8.4$), 7.66 (1H, d, $J = 1.4$). ^{13}C NMR (50 MHz, CDCl_3 , $\text{Z} + \text{E}$ Isomers): 13.4 (CH_3), 33.0 (CH_3), 53.7 (CH_3), 101.9 (CH), 102.1 (CH), 104.9 (CH), 105.6 (CH), 109.2 (CH), 109.5 (CH), 112.5 (CH), 113.5 (CH), 120.5 (CH), 121.5 (CH), 122.5 (CH), 122.7 (CH), 125.8 (C), 128.2 (C), 129.8 (CH), 136.9 (C), 137.4 (C), 144.8 (C), 147.9 (C), 157.0 (C), 157.2 (C), 157.6 (C), 157.9 (C), 163.9 (C). HRMS ($\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$): calcd 350.0933 ($\text{M} + \text{Na}^+$), found 350.0953. HPLC: C_{18} t_R : 18.39 min, t_R : 18.90 min.

4.1.2.43. Oximes of (4-(dimethylamino)phenyl)(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)methanone (36). Prepared according to procedure 3: 97 mg (0.31 mmol, 70%) of a 1:1 mixture of isomers **36(Z + E)**. M.p.: 142–144 °C ($\text{Hex}/\text{CH}_2\text{Cl}_2$). IR (KBr): 3364, 3267, 1602 cm^{-1} . ^1H NMR (200 MHz, CDCl_3 , Z Isomer): 2.58 (3H, s), 2.99 (6H, s), 3.98 (3H, s), 6.40 (1H, d, $J = 1.1$), 6.69 (2H, d, $J = 8.8$), 6.91 (1H, d, $J = 1.1$), 7.39 (2H, d, $J = 8.8$). ^1H NMR (200 MHz, CDCl_3 , E Isomer): 2.55 (3H, s), 3.03 (6H, s), 3.94 (3H, s), 6.47 (1H, d, $J = 1.1$),

6.83 (2H, d, $J = 8.8$), 6.95 (1H, d, $J = 1.1$), 7.35 (2H, d, $J = 8.8$). ^{13}C NMR (50 MHz, CDCl_3 , $\text{Z} + \text{E}$ Isomers): 13.5 (CH_3), 40.3 (2) (CH_3), 53.7 (CH_3), 105.2 (CH), 111.3 (2) (CH), 111.8 (2) (CH), 112.9 (CH), 113.4 (CH), 118.3 (C), 121.9 (C), 128.6 (2) (CH), 131.3 (2) (CH), 144.6 (C), 148.0 (C), 151.0 (C), 155.8 (C), 157.6 (C), 163.8 (C). HRMS ($\text{C}_{16}\text{H}_{19}\text{N}_3\text{O}_2\text{S}$): calcd 318.1270 ($\text{M} + \text{H}^+$), found 318.1283. HPLC: C_8 t_R : 17.85 min, t_R : 18.20 min.

4.1.2.44. 2-methoxy-4-(1-(4-methoxyphenyl)ethyl)-6-(methylsulfanyl)pyridine (37). A spatula of active Pd/C was added to a solution of **31** (46 mg, 0.16 mmol) in 5–10 mL of ethyl acetate/EtOH under H_2 atmosphere. After 24 h stirring at room temperature, the suspension was filtered through Celite and the solvent was evaporated. The product was purified by flash chromatography obtaining 8 mg (0.03 mmol, 17%) of compound **37**. Foam. IR (film): 1591 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 1.55 (3H, d, $J = 6.7$), 2.53 (3H, s), 3.79 (3H, s), 3.91 (3H, s), 3.95 (1H, q, $J = 6.7$), 6.26 (1H, s), 6.61 (1H, s), 6.83 (2H, d, $J = 8.3$), 7.11 (2H, d, $J = 8.3$). ^{13}C NMR (50 MHz, CDCl_3): 13.2 (CH_3), 21.1 (CH_3), 43.3 (CH), 53.3 (CH), 55.2 (CH_3), 104.3 (CH), 113.4 (CH), 113.8 (2) (CH), 114.1 (C), 128.4 (2) (CH), 136.5 (C), 156.7 (C), 158.6 (C), 164.0 (C). HRMS ($\text{C}_{16}\text{H}_{19}\text{NO}_2\text{S}$): calcd 290.1209 ($\text{M} + \text{H}^+$), found 290.1205. HPLC: C_8 t_R : 20.72 min.

4.1.2.45. (4-methoxy-3-nitrophenyl)(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)methanone (38). 0.43 mL of a 1:5 ($\text{HNO}_3/\text{water}$) (1.13 mmol) solution was added to 0.33 g (1.13 mmol) of compound **27** in H_2SO_4 (5.10 mL) at 0 °C. Five minutes later, it was poured onto a suspension of dichloromethane and anhydrous sodium carbonate. Then, it was filtered and evaporated to dryness under vacuum. The organic phase was purified by flash chromatography, obtaining 89 mg (0.27 mmol, 24%) of compound **38**. Foam. IR (film): 1667, 1611, 1540 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.58 (3H, s), 3.99 (3H, s), 4.05 (3H, s), 6.56 (1H, d, $J = 1.1$), 6.95 (1H, d, $J = 1.1$), 7.18 (1H, bd, $J = 8.9$), 8.03 (1H, dd, $J = 2.2$, $J = 8.9$), 8.30 (1H, d, $J = 2.2$). ^{13}C NMR (50 MHz, CDCl_3): 13.5 (CH_3), 54.0 (CH_3), 57.1 (CH_3), 104.9 (CH), 112.3 (CH), 113.4 (CH), 127.9 (CH), 128.3 (C), 135.9 (CH), 139.4 (C), 146.8 (C), 156.6 (C), 159.4 (C), 163.9 (C), 191.8 (C). HRMS ($\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_5\text{S}$): calcd 335.0696 ($\text{M} + \text{H}^+$), found 335.0716. HPLC: C_{18} t_R : 20.92 min.

4.1.2.46. (3-amino-4-methoxyphenyl)(2-methoxy-6-(methylsulfanyl)pyridin-4-yl)methanone (39). Fe (65 mg, 1.17 mmol) was added onto a solution of compound **38** (50 mg, 0.15 mmol) in 5 mL of ethanol, water and acetic acid in a 2:2:1 proportion and a drop of 37% HCl and was stirred at 100 °C for half an hour. The suspension was filtered through Celite and the solvent was evaporated in vacuum. The crude was re-dissolved in dichloromethane and washed with a 5% NaHCO_3 solution. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated. The product was purified by flash chromatography, to obtain 11 mg (0.04 mmol, 24%) of compound **39**. Foam. IR (film): 3368, 1654, 1543 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.58 (3H, s), 3.96 (3H, s), 3.99 (3H, s), 6.60 (1H, d, $J = 1.2$), 6.86 (1H, bd, $J = 8.8$), 6.97 (1H, d, $J = 1.2$), 7.36 (1H, dd, $J = 2.2$, $J = 8.8$), 7.51 (1H, d, $J = 2.2$). ^{13}C NMR (50 MHz, CDCl_3): 13.3 (CH_3), 53.8 (CH_3), 55.8 (CH_3), 105.1 (CH), 109.4 (CH), 112.6 (CH), 116.8 (CH), 124.0 (C), 124.4 (CH), 129.0 (C), 148.6 (C), 152.4 (C), 158.3 (C), 163.7 (C), 193.7 (C). HRMS ($\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$): calcd 305.0954 ($\text{M} + \text{H}^+$), found 305.0961. HPLC: C_8 t_R : 14.81 min.

4.1.2.47. 5-(2-methoxy-6-(methylsulfanyl)isonicotinoyl)-1-methyl-1H-indole-3-carbaldehyde (40). Prepared according to procedure 6: 145 mg (0.42 mmol, 51%). Foam. IR (film): 1654, 1614, 1591 cm^{-1} . ^1H NMR (200 MHz, CDCl_3): 2.59 (3H, s), 3.93 (3H, s), 4.00 (3H, s), 6.64 (1H, d, $J = 1.1$), 7.03 (1H, d, $J = 1.1$), 7.44 (1H, bd, $J = 8.9$), 7.78 (1H, s), 7.90 (1H, dd, $J = 1.4$, $J = 8.9$), 8.69 (1H, d, $J = 1.4$), 9.99 (1H, s). ^{13}C NMR (50 MHz, CDCl_3): 13.6 (CH_3), 34.0 (CH_3), 53.9 (CH_3), 105.5 (CH),

110.3 (CH), 112.8 (CH), 119.0 (C), 124.6 (C), 125.8 (2) (CH), 131.1 (C), 140.4 (C), 140.7 (CH), 148.5 (C), 158.6 (C), 160.8 (C), 184.3 (CHO), 195.2 (C). HRMS ($C_{18}H_{16}N_2O_3S$): calcd 341.0954 ($M + H^+$), found 341.0959. HPLC: C_8 t_R : 15.85 min.

4.1.2.48. (5-((hydroxyimino)(2-methoxy-6-(methylsulfonyl)pyridin-4-yl)methyl)-1-methyl-1H-indole-3-carbonitrile (42) and 5-(2-methoxy-6-(methylsulfonyl)isonicotinoyl)-1-methyl-1H-indole-3-carbonitrile (41). Prepared according to procedure 7: 10 mg (0.029 mmol, 15%) of 41, 5 mg (0.014 mmol, 7%) of 42E, 5 mg (0.014 mmol, 7%) of 42Z, and 9 mg (0.026, 13%) of a 1:1 mixture of oximes 42Z + E. Phenstatin 41 was recovered after dissolving oximes 42 in $CDCl_3$.

41: Foam. IR (film): 1661, 2221, 1609, 1542 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.55 (3H, s), 3.87 (3H, s), 3.95 (3H, s), 6.56 (1H, d, $J = 1.2$), 6.96 (1H, d, $J = 1.2$), 7.43 (1H, d, $J = 8.4$), 7.62 (1H, s), 7.86 (1H, dd, $J = 1.6$, $J = 8.4$), 8.11 (1H, d, $J = 1.6$). ^{13}C NMR (50 MHz, $CDCl_3$): 13.4 (CH_3), 33.9 (CH_3), 53.8 (CH_3), 105.2 (CH), 110.6 (CH), 112.6 (CH), 114.7 (C), 115.6 (C), 123.8 (CH), 125.5 (CH), 127.0 (C), 130.5 (C), 137.3 (CH), 148.2 (C), 158.8 (C), 163.6 (C), 194.8 (C). HRMS ($C_{18}H_{15}N_3O_2S$): calcd 338.0958 ($M + H^+$), found 338.0943. HPLC: C_8 t_R : 17.89 min.

42E: Amorphous solid. IR (film): 3309, 2221, 1590 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.50 (3H, s), 3.84 (3H, s), 3.87 (3H, s), 6.33 (1H, d, $J = 1.2$), 6.86 (1H, d, $J = 1.2$), 7.26 (1H, bd, $J = 8.8$), 7.41 (1H, d, $J = 8.8$), 7.57 (1H, s), 7.72 (1H, bs). HRMS ($C_{18}H_{16}N_4O_2S$): calcd 353.1067 ($M + H^+$), found 353.1069. HPLC: C_8 t_R : 15.80 min.

42Z: Amorphous solid. IR (film): 3309, 2221, 1591 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.54 (3H, s), 3.80 (3H, s), 3.95 (3H, s), 6.34 (1H, d, $J = 1.2$), 6.68 (1H, s, $J = 1.2$), 7.30 (1H, d, $J = 8.8$), 7.52 (1H, bs), 7.55 (1H, bd, $J = 8.8$), 7.65 (1H, s). HRMS ($C_{18}H_{16}N_4O_2S$): calcd 353.1067 ($M + H^+$), found 353.1071. HPLC: C_8 t_R : 16.72 min.

4.1.2.49. 5-(1-(2-methoxy-6-(methylsulfonyl)pyridin-4-yl)vinyl)-1-methyl-1H-indole-3-carbaldehyde (43). Prepared according to procedure 6: 52 mg (0.15 mmol, 59%). Oil. IR (film): 1658, 1589 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.53 (3H, s), 3.85 (3H, s), 3.94 (3H, s), 5.56 (1H, s), 5.57 (1H, s), 6.36 (1H, d, $J = 1.1$), 6.73 (1H, d, $J = 1.1$), 7.20 (1H, dd, $J = 1.4$, $J = 8.9$), 7.26 (1H, bd, $J = 8.9$), 7.66 (1H, s), 8.28 (1H, d, $J = 1.4$), 9.94 (1H, s). ^{13}C NMR (50 MHz, $CDCl_3$): 13.4 (CH_3), 33.8 (CH_3), 53.5 (CH_3), 104.9 (CH), 109.7 (CH), 113.3 (CH), 116.2 (CH_2), 118.2 (C), 121.7 (CH), 124.7 (CH), 125.3 (C), 135.3 (C), 137.7 (C), 139.9 (CH), 148.2 (C), 152.6 (C), 157.1 (C), 164.0 (C), 184.4 (CHO). HRMS ($C_{19}H_{17}N_2O_2S$): calcd 361.0981 ($M + H^+$), found 361.0992. HPLC: C_8 t_R : 19.29 min.

4.1.2.50. 5-(1-(2-methoxy-6-(methylsulfonyl)pyridin-4-yl)vinyl)-1-methyl-1H-indole-3-carboxylic acid (44). 172 μL (0.325 mmol) of 20% phosgene in toluene were added onto 101 mg (0.325 mmol) of compound 32 in 20 mL of dichloromethane. The reaction was monitored by 1H NMR, and, after 24 h, 172 μL (0.325 mmol) of 20% phosgene in toluene were added. After 72 h, the reaction was poured onto ice water. The solution was basified with 5% NaOH and extracted with ethyl acetate (organic phase A). The aqueous phase was acidified with 2 N HCl, and extracted with dichloromethane (organic phase B). The organic phase B was washed with brine, dried over anhydrous Na_2SO_4 , filtered and evaporated to dryness to obtain 31 mg (0.087 mmol, 27%) of compound 44. Amorphous solid. IR (film): 1660, 1591 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.55 (3H, s), 3.86 (3H, s), 3.95 (3H, s), 5.59 (2H, s), 6.40 (1H, s), 6.76 (1H, s), 7.15 (1H, d, $J = 8.9$), 7.30 (1H, bd, $J = 8.9$), 7.90 (1H, bs), 8.22 (1H, s). ^{13}C NMR (50 MHz, $CDCl_3$): 13.5 (CH_3), 33.7 (CH_3), 53.9 (CH_3), 104.9 (CH), 106.6 (C), 109.7 (CH), 113.4 (CH), 116.5 (CH_2), 121.5 (CH), 123.8 (CH), 126.9 (C), 134.6 (C), 137.2 (CH), 148.5 (C), 152.7 (C), 157.1 (C), 164.0 (C), 170.2 (C). HRMS ($C_{19}H_{18}N_2O_3S$): calcd 355.1110 ($M + H^+$), found 355.1113. HPLC: C_8 t_R : 20.28 min.

4.1.2.51. (2-methoxy-6-(methylsulfonyl)pyridin-4-yl)(naphthalen-2-yl)methanone (45) and (2-methoxy-6-(methylsulfonyl)pyridin-4-yl)(naphthalen-2-yl)methanone (46). 97 mg (0.57 mmol) of mCPBA was added onto a solution of 175 mg (0.57 mmol) of compound 26 in 10 mL of dichloromethane and stirred for 24 h at 0 °C. Sodium bisulfite was added and the solution was extracted with ethyl acetate, washed with water and a 5% solution of sodium bicarbonate. The organic layers were dried over Na_2SO_4 , filtered, evaporated and purified by flash chromatography to obtain 49 mg (0.15 mmol, 26.3%) of compound 45 and 19 mg (0.06 mmol, 10.5%) of compound 46.

45: Foam. IR (film): 1665, 1600, 1543 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.91 (3H, s), 4.02 (3H, s), 7.12 (1H, d, $J = 1.4$), 7.5–7.7 (3H, m), 7.87 (1H, d, $J = 1.4$), 7.9–8.0 (3H, m), 8.25 (1H, bs). ^{13}C NMR (50 MHz, $CDCl_3$): 40.8 (CH_3), 54.5 (CH_3), 112.4 (CH), 112.6 (CH), 124.9 (CH), 127.1 (CH), 127.9 (CH), 129.1 (CH), 129.2 (CH), 129.8 (CH), 132.2 (2) (C), 132.7 (CH), 135.8 (C), 149.6 (C), 163.9 (C), 164.3 (C), 193.9 (C). HRMS ($C_{18}H_{15}NO_3S$): calcd 326.0846 ($M + H^+$), found 326.0849. HPLC: C_{18} t_R : 16.39 min.

46: Foam. IR (film): 1665, 1603, 1543 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 3.26 (3H, s), 4.09 (3H, s), 7.29 (1H, d, $J = 1.2$), 7.5–7.7 (3H, m), 7.98 (1H, d, $J = 1.2$), 7.9–8.0 (3H, m), 8.22 (1H, bs). ^{13}C NMR (50 MHz, $CDCl_3$): 39.8 (CH_3), 54.8 (CH_3), 113.5 (CH), 115.9 (CH), 124.7 (CH), 127.3 (CH), 127.9 (CH), 129.1 (CH), 129.3 (CH), 129.8 (CH), 132.1 (C), 132.4 (C), 132.8 (CH), 135.8 (C), 149.7 (C), 155.6 (C), 164.5 (C), 193.1 (C). HRMS ($C_{18}H_{15}NO_4S$): calcd 342.3884 ($M + H^+$), found 342.3893. HPLC: C_{18} t_R : 16.81 min.

4.1.2.52. (2-methoxy-6-(methylsulfonyl)pyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (47). 180 mg (1.04 mmol) of mCPBA was added onto a solution of 325 mg (1.04 mmol) of compound 28 in 10 mL of dichloromethane and stirred for 24 h at 0 °C. Sodium bisulfite was added and the solution was extracted in ethyl acetate, washed with water and a solution of 5% sodium bicarbonate. The organic layers were dried over Na_2SO_4 , filtered, evaporated and purified by flash chromatography to obtain 48 mg (0.146 mmol, 14%) of compound 47. Foam. IR (film): 1656, 1602, 1543 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 2.90 (3H, s), 3.85 (3H, s), 4.00 (3H, s), 6.59 (1H, d, $J = 3.0$), 7.07 (1H, d, $J = 1.2$), 7.15 (1H, d, $J = 3.0$), 7.39 (1H, bd, $J = 8.6$), 7.82 (1H, dd, $J = 1.8$, $J = 8.6$), 7.82 (1H, d, $J = 1.2$), 8.08 (1H, d, $J = 1.8$). ^{13}C NMR (50 MHz, $CDCl_3$): 33.2 (CH_3), 40.8 (CH_3), 54.4 (CH_3), 103.5 (CH), 109.7 (CH), 111.9 (CH), 112.4 (CH), 123.5 (CH), 125.9 (CH), 127.2 (C), 127.9 (C), 131.0 (CH), 139.6 (C), 151.2 (C), 163.3 (C), 164.2 (C), 194.5 (C). HRMS ($C_{17}H_{16}N_2O_3S$): calcd 329.0954 ($M + H^+$), found 329.0968. HPLC: C_{18} t_R : 15.62 min.

4.1.2.53. (2-methoxy-6-(methylsulfonyl)pyridin-4-yl)(1-methyl-1H-indol-5-yl)methanone (48). 185 mg (1.07 mmol) of mCPBA was added onto a solution of 224 mg (0.72 mmol) of compound 47 in 10 mL of dichloromethane and stirred for 24 h at 0 °C. Sodium bisulfite was added and the solution was extracted in ethyl acetate, washed with water and a solution of 5% sodium bicarbonate. The organic layers were dried over Na_2SO_4 , filtered, evaporated and purified by flash chromatography to obtain 8 mg (0.02 mmol, 3.2%) of compound 48. Foam. IR (film): 1658, 1604, 1543 cm^{-1} . 1H NMR (200 MHz, $CDCl_3$): 3.24 (3H, s), 3.85 (3H, s), 4.07 (3H, s), 6.60 (1H, d, $J = 3.2$), 7.16 (1H, d, $J = 3.2$), 7.25 (1H, d, $J = 1.1$), 7.42 (1H, d, $J = 8.6$), 7.79 (1H, dd, $J = 1.8$, $J = 8.6$), 7.93 (1H, d, $J = 1.1$), 8.05 (1H, d, $J = 1.8$). ^{13}C NMR (50 MHz, $CDCl_3$): 33.1 (CH_3), 39.8 (CH_3), 54.6 (CH_3), 103.5 (CH), 109.7 (CH), 113.7 (CH), 115.6 (CH), 123.3 (CH), 125.9 (CH), 126.9 (C), 127.9 (C), 131.0 (CH), 139.6 (C), 151.2 (C), 155.1 (C), 164.3 (C), 193.2 (C). HRMS ($C_{19}H_{18}N_2O_3S$): calcd 345.0903 ($M + H^+$), found 345.0911. HPLC: C_{18} t_R : 10.57 min.

4.1.3. Determination of aqueous solubility

The aqueous solubility of the compounds was determined using an approach based on the saturation shake-flask method. Approximately

2 mg of each compound was suspended in 0.3 mL pH 7.0 buffer in a glass vial and shaken 72 h at room temperature. The resulting mixture was filtrated over a 45 µm filter to discard the insoluble residues and the concentration in the supernatant was measured by UV absorbance in a Helios Alfa Spectrophotometer. Previously, for each compound, we determined the maximum absorbance wavelength and a calibration curve was obtained.

4.2. Biology

4.2.1. Inhibition of tubulin polymerization

Bovine brain tubulin was isolated as previously described [23]. The assays were carried out at pH 6.7 with 1.5 mg/mL protein and the measured ligand concentration in 0.1 M MES buffer, 1 mM EGTA, 1 mM MgCl₂, 1 mM β-ME, 1.5 mM GTP. The samples were incubated at 20 °C for 30 min and subsequently cooled on ice for 10 min. Tubulin polymerization was monitored by measuring the turbidimetry increase in the UV at 450 nm caused by a temperature shift from 4 °C to 37 °C. After reaching a stable plateau, temperature was switched back to 4 °C and return to the initial absorption values was ascertained, in order to confirm the reversible nature of the monitored process. The difference in amplitude between the stable plateau and the initial baseline of the curves was taken as the degree of tubulin assembly for each experiment. Comparison with control curves with identical conditions but without ligands yielded tubulin polymerization inhibition as a percentage value. Initially, all compounds were assayed at a concentration of 5 µM in at least two independent measurements, and those displaying a TPI higher than 40% were selected for further studies. The tubulin polymerization inhibitory activity of the selected compounds was measured at different ligand concentrations and, as expected, the extent of inhibition by all compounds increased monotonically with the mole ratio of the total ligand to total tubulin in the solution. The obtained values were fitted to monoexponential curves and the IC₅₀ values of tubulin polymerization inhibition were calculated from the best fitting curves.

4.2.2. Cell culture

HL-60 (human acute myeloid leukemia) and HT-29 (human colon carcinoma) cell lines were grown in RPMI-1640 culture medium containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in humidified 95% air and 5% CO₂. HeLa (human cervical carcinoma) cell line was grown in DMEM culture medium containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in humidified 95% air and 5% CO₂. Cells were periodically tested for *Mycoplasma* infection and found to be negative.

4.2.3. Cell growth inhibition assay

The effect of the different compounds on the proliferation of human tumour cell lines (cytostatic activity) was determined as previously described [27] using the XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)-benzenesulfonic acid hydrate) cell proliferation kit (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. Cells (1.5 × 10³ HeLa, 3 × 10³ HT-29 and 5 × 10³ HL-60 in 100 µL) were incubated in culture medium containing 10% heat-inactivated FBS, in the absence and in the presence of the indicated compounds at different concentration ranges from 10⁻⁵ to 10⁻¹³ M, in 96-well flat-bottomed microtiter plates, and following 72 h of incubation at 37 °C in a humidified atmosphere of air/CO₂ (19/1), the XTT assay was performed. Measurements were performed in triplicate, and each experiment was repeated three times. The IC₅₀ (50% inhibitory concentration) value, defined as the drug concentration required to cause 50% inhibition in cellular proliferation with respect to the untreated controls, was determined for each compound. Nonlinear curve fitting of the experimental data was carried out for each compound.

4.2.4. Cell cycle analysis

For cell cycle analyses, untreated and drug-treated cells (2–4 × 10⁵) were centrifuged and fixed overnight in 70% ethanol at 4 °C. Then cells were washed three times with PBS, incubated for 1 h with 1 mg/mL RNase A and 20 µg/mL propidium iodide at room temperature, and analyzed with a Becton Dickinson fluorescence-activated cell sorter (FACSCalibur) flow cytometer (San Jose, CA) as previously described [34,35]. Quantification of apoptotic cells was calculated as the percentage of cells in the sub-G₀/G₁ region in cell cycle analysis [34,35].

4.2.5. Confocal microscopy

HeLa cells were grown on 0.01% poly-L-lysine coated coverslips, and after drug treatment, the coverslips were washed three times with HPEM buffer (25 mM HEPES, 60 mM PIPES, 10 mM EGTA, 3 mM MgCl₂, pH 6.6), fixed with 4% formaldehyde in HPEM buffer for 20 min, and permeabilized with 0.5% Triton X-100 as previously described [21]. Coverslips were incubated with a specific Ab-1 anti-α-tubulin mouse monoclonal antibody (diluted 1:150 in PBS) (Calbiochem, San Diego, CA) for 1 h, washed four times with PBS, and then incubated with CY3-conjugated sheep antimouse IgG (diluted 1:100 in PBS) (Jackson ImmunoResearch, West Grove, PA) for 1 h at 4 °C. After four washes with PBS, a drop of SlowFade light antifading reagent (Molecular Probes, Eugene, OR), with DAPI (Sigma, St. Louis, MO) to stain cell nuclei, was added to preserve fluorescence. The samples were analyzed by confocal microscopy using a Zeiss LSM 310 laser scan confocal microscope. Negative controls, lacking the primary antibody or using an irrelevant antibody, showed no staining.

4.3. Computational studies

4.3.1. Chemical structure

Calculations were performed at the molecular mechanics level (MMFF94s), semiempirical level (AM1), and B3LYP 6-31 + G* DFT levels using the Spartan 08 software package. Conformational analyses with the MMFF94s forcefield were performed by systematically rotating in 18° steps the bonds between the rings and the pending substituents and subjected to further unrestrained energy minimization steps at the B3LYP/6-31 + G* DFT level of theory.

4.3.2. Docking experiments

The coordinates of the tubulin – colchicine site ligands complexes available were retrieved from the pdb [36] and chains C – E were removed. Five additional tubulin models were built from 1SA1.pdb after energy minimization and molecular dynamics simulations at 300 K, initially with a restrained backbone and then with an unrestrained one using AMBER14 [37] and representative structures were selected as previously described [28]. The ligands were built with Spartan 08 [38], prepared with AutodockTools and docked with AutoDock 4.2 [30,39], by running the Lamarckian genetic algorithm (LGA) 100–300 times with a maximum of 2.5 × 10⁶ energy evaluations, 150 individuals in the population, and a maximum of 27,000 generations, and PLANTS [29]. The binding poses were automatically classified by the binding pockets they occupy and the results tabulated using KNIME pipelines. The binding energies assigned by every docking program to all the poses were automatically converted to z-scores by dividing the energy difference of each pose to the highest pose by the difference between the highest and the lowest values for that compound. The 0–1 valued z-scores were used for ranking the docking poses in a way independent of the program used to score the poses. The results were analyzed with Chimera [40], AutoDockTools [30,39], Marvin [41], OpenEye [42] and with JADOPPT [43]. Docking poses were selected if they were found by the two docking programs in the two first quartiles and above any alternative based on the combined z scoring.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank the people at Frigoríficos Salamanca S.A. slaughter-house for providing us with the calf brains and “Servicio General de NMR” and “Servicio General de Espectrometría de Masas” of the Universidad de Salamanca for equipment. L.A. acknowledges a predoctoral fellowship from the Junta de Castilla y León. A.V.B acknowledges a predoctoral fellowship from the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/02457).

Funding sources

This work was supported by the Consejería de Educación de la Junta de Castilla y León (SA030U16 and SA262P18), co-funded by the EU's European Regional Development Fund-FEDER, and the Spanish Ministry of Science, Innovation and Universities (RTI2018-099474-B-I00 and SAF2017-89672-R).

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bioorg.2020.103755>.

References

- [1] C. Dumontet, M.A. Jordan, Microtubule-binding agents: a dynamic field of cancer therapeutics, *Nat. Rev. Drug Discovery* 9 (2010) 790–803, <https://doi.org/10.1038/nrd3253>.
- [2] A. Vicente-Blazquez, M. Gonzalez, R. Alvarez, S. Del Mazo, M. Medarde, R. Pelaez, Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target, *Med. Res. Rev.* (2018), <https://doi.org/10.1002/med.21541>.
- [3] F. Mollinedo, C. Gajate, Microtubules, microtubule-interfering agents and apoptosis, *Apoptosis: Int. J. Programmed Cell Death* 8 (2003) 413–450, <https://doi.org/10.1023/A:1025513106330>.
- [4] M.J. Perez-Perez, E.M. Priego, O. Bueno, M.S. Martins, M.D. Canela, S. Liekens, Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth, *J. Med. Chem.* 59 (2016) 8685–8711, <https://doi.org/10.1021/acs.jmedchem.6b00463>.
- [5] S.J. Lunt, S. Akerman, S.A. Hill, M. Fisher, V.J. Wright, C.C. Reyes-Aldasoro, G.M. Tozer, C. Kanthou, Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate, *Int. J. Cancer* 129 (2011) 1979–1989, <https://doi.org/10.1002/ijc.25848>.
- [6] D.W. Siemann, The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents, *Cancer Treat. Rev.* 37 (2011) 63–74, <https://doi.org/10.1016/j.ctrv.2010.05.001>.
- [7] W. Liang, Y. Ni, F. Chen, Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions, *Oncotarget* 7 (2016) 15444–15459, <https://doi.org/10.18632/oncotarget.6999>.
- [8] G.M. Tozer, C. Kanthou, G. Lewis, V.E. Prise, B. Vojnovic, S.A. Hill, Tumour vascular disrupting agents: combating treatment resistance, *Br. J. Radiol.* 81 Spec No 1 (2008) S12–20. doi: 10.1259/bjr/36205483.
- [9] G.C. Tron, T. Pirali, G. Sorba, F. Pagliari, S. Busacca, A.A. Genazzani, Medicinal chemistry of combretastatin A4: present and future directions, *J. Med. Chem.* 49 (2006) 3033–3044, <https://doi.org/10.1021/jm0512903>.
- [10] S. Aprile, E. Del Grosso, G.C. Tron, G. Grosa, In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes, *Drug Metabolism Disposition: Biol. Fate Chem.* 35 (2007) 2252–2261, <https://doi.org/10.1124/dmd.107.016998>.
- [11] G.R. Pettit, B. Toki, D.L. Herald, P. Verdier-Pinard, M.R. Boyd, E. Hamel, R.K. Pettit, Antineoplastic agents. 379. Synthesis of phenstatin phosphate, *J. Med. Chem.* 41 (1998) 1688–1695, <https://doi.org/10.1021/jm970644q>.
- [12] A.M. Malebari, L.M. Greene, S.M. Nathwani, D. Fayne, N.M. O'Boyle, S. Wang, B. Twamley, D.M. Zisterer, M.J. Meegan, beta-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, *Eur. J. Med. Chem.* 130 (2017) 261–285, <https://doi.org/10.1016/j.ejmech.2017.02.049>.
- [13] R. Kaur, G. Kaur, R.K. Gill, R. Soni, J. Bariwal, Recent developments in tubulin polymerization inhibitors: An overview, *Eur. J. Med. Chem.* 87 (2014) 89–124, <https://doi.org/10.1016/j.ejmech.2014.09.051>.
- [14] Y. Lu, J. Chen, M. Xiao, W. Li, D.D. Miller, An overview of tubulin inhibitors that interact with the colchicine binding site, *Pharm. Res.* 29 (2012) 2943–2971, <https://doi.org/10.1007/s11095-012-0828-z>.
- [15] R. Alvarez, C. Alvarez, F. Mollinedo, B.G. Sierra, M. Medarde, R. Pelaez, Isocombreastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds, *Bioorg. Med. Chem.* 17 (2009) 6422–6431, <https://doi.org/10.1016/j.bmc.2009.07.012>.
- [16] N. Sirisoma, A. Pervin, H. Zhang, S. Jiang, J.A. Willardsen, M.B. Anderson, G. Mather, C.M. Pleiman, S. Kasibhatla, B. Tseng, J. Drewe, S.X. Cai, Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration, *J. Med. Chem.* 52 (2009) 2341–2351, <https://doi.org/10.1021/jm801315b>.
- [17] T.M. Beale, D.M. Allwood, A. Bender, P.J. Bond, J.D. Brenton, D.S. Charnock-Jones, S.V. Ley, R.M. Myers, J.W. Shearman, J. Temple, J. Unger, C.A. Watts, J. Xian, A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles, *ACS Med. Chem. Lett.* 3 (2012) 177–181, <https://doi.org/10.1021/ml200149g>.
- [18] R. Alvarez, L. Aramburu, P. Puebla, E. Caballero, M. Gonzalez, A. Vicente, M. Medarde, R. Pelaez, Pyridine based antitumour compounds acting at the colchicine site, *Curr. Med. Chem.* 23 (2016) 1100–1130, <https://doi.org/10.2174/092986732311160420104823>.
- [19] F. Xu, W. Li, W. Shuai, L. Yang, Y. Bi, C. Ma, H. Yao, S. Xu, Z. Zhu, J. Xu, Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents, *Eur. J. Med. Chem.* 173 (2019) 1–14, <https://doi.org/10.1016/j.ejmech.2019.04.008>.
- [20] C. Alvarez, R. Alvarez, P. Corchete, C. Perez-Melero, R. Pelaez, M. Medarde, Naphthylphenstatins as tubulin ligands: synthesis and biological evaluation, *Bioorg. Med. Chem.* 16 (2008) 8999–9008, <https://doi.org/10.1016/j.bmc.2008.08.040>.
- [21] A.B. Maya, C. Perez-Melero, C. Mateo, D. Alonso, J.L. Fernandez, C. Gajate, F. Mollinedo, R. Pelaez, E. Caballero, M. Medarde, Further naphthylcombreastatins. An investigation on the role of the naphthalene moiety, *J. Med. Chem.* 48 (2005) 556–568, <https://doi.org/10.1021/jm0310737>.
- [22] R. Alvarez, C. Gajate, P. Puebla, F. Mollinedo, M. Medarde, R. Pelaez, Substitution at the indole 3 position yields highly potent indolecombreastatins against human tumor cells, *Eur. J. Med. Chem.* 158 (2018) 167–183, <https://doi.org/10.1016/j.ejmech.2018.08.078>.
- [23] R. Alvarez, P. Puebla, J.F. Diaz, A.C. Bento, R. Garcia-Navas, J. de la Iglesia-Vicente, F. Mollinedo, J.M. Andreu, M. Medarde, R. Pelaez, Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombreastatins, *J. Med. Chem.* 56 (2013) 2813–2827, <https://doi.org/10.1021/jm3015603>.
- [24] C. Jimenez, Y. Ellahioui, R. Alvarez, L. Aramburu, A. Riesco, M. Gonzalez, A. Vicente, A. Dahdouh, A. Ibn Mansour, C. Jimenez, D. Martin, R.G. Sarmiento, M. Medarde, E. Caballero, R. Pelaez, Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombreastatins, *Eur. J. Med. Chem.* 100 (2015) 210–222, <https://doi.org/10.1016/j.ejmech.2015.05.047>.
- [25] K.E. Henegar, S.W. Ashford, T.A. Baughman, J.C. Sih, R.-L. Gu, Practical Asymmetric Synthesis of (S)-4-Ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione, a Key Intermediate for the Synthesis of Irinotecan and Other Camptothecin Analogs, *J. Organic Chem.* 62 (1997) 6588–6597, <https://doi.org/10.1021/jo970173f>.
- [26] J. Chen, Z. Wang, C.M. Li, Y. Lu, P.K. Vaddady, B. Meibohm, J.T. Dalton, D.D. Miller, W. Li, Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents, *J. Med. Chem.* 53 (2010) 7414–7427, <https://doi.org/10.1021/jm100884b>.
- [27] M.H. David-Cordonnier, C. Gajate, O. Olmea, W. Laine, J. de la Iglesia-Vicente, C. Perez, C. Cuevas, G. Otero, I. Manzanares, C. Bailly, F. Mollinedo, DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin, *Chem. Biol.* 12 (2005) 1201–1210, <https://doi.org/10.1016/j.chembiol.2005.08.009>.
- [28] R. Alvarez, M. Medarde, R. Pelaez, New ligands of the tubulin colchicine site based on X-ray structures, *Curr. Top. Med. Chem.* 14 (2014) 2231–2252, <https://doi.org/10.2174/1568026614666141130092637>.
- [29] O. Korb, T. Stutzle, T.E. Exner, Empirical scoring functions for advanced protein-ligand docking with PLANTS, *J. Chem. Inf. Model.* 49 (2009) 84–96, <https://doi.org/10.1021/ci800298z>.
- [30] S. Forli, R. Huey, M.E. Pique, M.F. Sanner, D.S. Goodsell, A.J. Olson, Computational protein-ligand docking and virtual drug screening with the AutoDock suite, *Nat. Protoc.* 11 (2016) 905–919, <https://doi.org/10.1038/nprot.2016.051>.
- [31] A. Massarotti, A. Coluccia, R. Silvestri, G. Sorba, A. Brancale, The tubulin colchicine domain: a molecular modeling perspective, *ChemMedChem* 7 (2012) 33–42, <https://doi.org/10.1002/cmdc.201100361>.
- [32] R. Gaspari, A.E. Prota, K. Bargsten, A. Cavalli, M.O. Steinmetz, Structural Basis of cis- and trans-Combreastatin Binding to Tubulin, *Chem* 2 (2017) 102–113, <https://doi.org/10.1016/j.chempr.2016.12.005>.
- [33] S. Banerjee, K.E. Arnst, Y. Wang, G. Kumar, S. Deng, L. Yang, G.B. Li, J. Yang, S.W. White, W. Li, D.D. Miller, Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy, *J. Med. Chem.* 61 (2018) 1704–1718, <https://doi.org/10.1021/acs.jmedchem.7b01858>.
- [34] C. Gajate, A.M. Santos-Beneit, A. Macho, M. Lazaro, A. Hernandez-De Rojas, M. Modolell, E. Munoz, F. Mollinedo, Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells, *Int. J. Cancer* 86 (2000) 208–218.
- [35] C. Gajate, I. Barasoain, J.M. Andreu, F. Mollinedo, Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2,3,4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-X(L)

- and cell cycle arrest, *Cancer Res.* 60 (2000) 2651–2659.
- [36] S. Aprile, E. Del Grosso, G. Grosa, Identification of the human UDP-glucuronosyl-transferases involved in the glucuronidation of combretastatin A-4, *Drug Metabolism Disposition: Biol. Fate Chem.* 38 (2010) 1141–1146, <https://doi.org/10.1124/dmd.109.031435>.
- [37] D.A. Case, T.E. Cheatham 3rd, T. Darden, H. Gohlke, R. Luo, K.M. Merz Jr., A. Onufriev, C. Simmerling, B. Wang, R.J. Woods, The Amber biomolecular simulation programs, *J. Comput. Chem.* 26 (2005) 1668–1688, <https://doi.org/10.1002/jcc.20290>.
- [38] I. WAVEFUNCTION, Spartan08, in, 2008.
- [39] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, *J. Comput. Chem.* 30 (2009) 2785–2791, <https://doi.org/10.1002/jcc.21256>.
- [40] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera—a visualization system for exploratory research and analysis, *J. Comput. Chem.* 25 (2004) 1605–1612, <https://doi.org/10.1002/jcc.20084>.
- [41] Marvin 17.8 in, ChemAxon (<http://www.chemaxon.com>), 2017.
- [42] OpenEye Scientific Software, Inc, Santa Fe in OpenEye (<https://www.eyesopen.com>), 2019.
- [43] C. Garcia-Perez, R. Pelaez, R. Theron, J. Luis Lopez-Perez, JADOPPT: java based AutoDock preparing and processing tool, *Bioinformatics* 33 (2017) 583–585, <https://doi.org/10.1093/bioinformatics/btw677>.